alexander & ann shulgin - pihkal - a chemical love story - appendices

Long Index to Book II

APPENDIX A: LONG INDEX TO BOOK II

A see under B, #10 AAM see under AEM, #1 ABM see under AEM, #1 4-Acetamido-2,5-dimethoxyamphetamine see under DOC, #64 B-Acetoxy-2-CD see under BOHD, #16 B-Acetoxy-2,5-dimethoxy-4-methylphenethylamine see under BOHD, #16 N-Acetyl-3,4-dimethoxyphenethylamine see under DMPEA, #60 N-Acetyl-DMPEA see under DMPEA, #60 N-Acetyl-MDA see under MOE, #105 N-Acetyl-mescaline see under M, #96 N-Acetyl-3,4-methylenedioxyamphetamine see under MOE, #105 N-Acetyl-3,4,5-trimethoxyphenethylamine see under M, #96 Acoramone see under TMA, #157 Acorus see under TMA, #157 ADAM see MDMA, #109 Adrenochrome see under TMA, #157 Adrenolutin see under TMA, #157 AEM #1 page 458 AHM see under AEM, #I AL #2 page 460 ALEPH #3 page 462 ALEPH-I see ALEPH, #3 ALEPH-2 #4 page 464 ALEPH-3 see under ALEPH-2, #4 ALEPH-4 #5 page 468 ALEPH-5 see under ALEPH-2, #4 ALEPH-6 #6 page 469 ALEPH-7 #7 page 472

925

926 PIHKAL- A Chemical Love Story

ALEPH-S see under 2C-T-8, #44 ALEPH-9 see under 2C-T-9, #45 ALEPH-16 see under ALEPH-2, #4 ALEPH-20 see under ALEPH-2, #4 ALEPH-21 see under 2C-T-21, #49 Aleph State see under ALEPH, #3 Allspice see underTMA, #157 4-Allylanisole see under 4-MA, #97 4-Allylguaiacol see under TMA, #157 N-Allyl-MDA see MDAL, #101 N-Allyl-3,4-methylenedioxyamphetamine see MDAL, #101 4-Allyloxy-3,5-dimethoxyamphetamine see under AL, #2 4-Allyloxy-3,5-dimethoxyphenethylamine see AL, #2 4-Allyloxy-3-methoxyamphetamine see under MEPEA, #123 4-Allyloxy-3-methoxyphenethylamine see under MEPEA, #123 4-Allyl-2,3,4,5-tetramethoxybenzene see under TA, #145 4-Allylthio-2,5-dimethoxyphenethylamine see under ALEPH-2, #4 ALPHA see under MDA, #100 2-Aminoindanes see under PEA, #142 4-Amino-2,5-dimethoxyamphetamine see under DOC, #64 2-Amino-1-(2,5-dimethoxy-4-bromophenyl)butane see under ARIADNE, #8 2-Amino-3-(2,5-dimethoxy-3,4-methylenedioxyphenyl)butane see under

DMMDA,#58 2-Amino-1-(2,5-dimethoxy-4-methylphenyl)butane see ARIADNE, #8 2-Amino-1-(2,5-dimethoxyphenyl)butane see under ARIADNE, #8 4-(2-Aminoethyl)-3,6-dimethoxybenzonorbornane see 2C-G-5, #30 5-(2-Aminoethyl)-4,7-dimethoxyindane see 2C-G-3, #28 6-(2-Aminoethyl)-5,8-dimethoxytetralin see 2C-G-4, #29 2-Amino-1-(3,4-methylenedioxyphenyl)butane see J, #94 2-Amino-3-(3,4-methylenedioxyphenyl)butane see under DMMDA, #58 3-Amino-1-(3,4-methylenedioxyphenyl)butane see under PEA, # 142 2-Amino-1-(3,4-methylenedioxyphenyl)hexane see under METHYL-K, #129 2-Amino-1-(3,4-methylenedioxyphenyl)pentane see under METHYL-K, #129 1-Amino-1-(3,4-methylenedioxyphenyl)propane see under MDA, #100 1-Amino-3-(3,4-methylenedioxyphenyl)propane see under MDA, #100 4-(2-Aminopropyl)-3,6-dimethoxybenzonorbornane see G-5, #84 5-(2-Aminopropyl)-4,7-dimethoxyindane see G-3, #82 6-(2-Aminopropyl)-5,8-dimethoxytetralin see G-4, #83 6-(2-Aminopropyl)-2,2-dimethyl-5-methoxy-2,3-dihydrobenzofuran see F-22,

#80 6-(2-Aminopropyl)-2,3-dimethyl-5-methoxy-2,3-dihydrobenzofuran see under

F-22, #80 7-(2-Aminopropyl)-2,2-dimethyl-5-methoxy-2,3-dihydrobenzofuran see under


F-22, #80 6-(2-Aminopropyl)-2-ethyl-5-methoxy-2,3-dihydrobenzofuran see under F-22,

#80 5-(2-Aminopropyl)-6-methoxy-1 ,3-benzoxathiol see under 4T -MMDA- 2,

#167 5-(2-Aminopropyl)-7 -methoxy-1 ,3-benzoxathiol see under 2T-MMDA- 3a,

#166 6-(2-Aminopropyl)-5-methoxy-l ,3-benzoxathiol see 4T -MMDA-2, #167 6-(2-Aminopropyl)-5-methoxy-2,3-dihydrobenzofuran see under F- 2, #79 6-(2-Aminopropyl)-5-methoxy-2-methyl-2,3-dihydrobenzofuran see F-2, #79 7-(2-Aminopropyl)-5-methoxy-2-methyl-2,3-dihydrobenzofuran see under F-

22,#80 7 -(2-Aminopropyl)-6-methoxy-1 ,2,3,4-tetrahydrobenzopyran see under F-22,

#80 6-(2-Aminopropy 1 )-5-methoxy-2,3 ,3-trimethy I-2,3-dihydrobenzofuran see

under F-22, #80 2-Aminotetralins see under PEA, #142 2-Amino-1-(2,4,6-trimethoxyphenyl)butane see under ARIADNE, #8 2-Amino-1-(3,4,5-trimethoxyphenyl)butane see AEM, #1 2-Amino-1-(3,4,5-trimethoxyphenyl)decane see under AEM, #1 2-Amino-1-(3,4,5-trimethoxyphenyl)heptane see under AEM, #1 2-Amino-1-(3,4,5-trimethoxyphenyl)hexane see under AEM, #I 2-Amino-1-(3,4,5-trimethoxyphenyl)nonane see under AEM, #1 2-Amino-1-(3,4,5-trimethoxyphenyl)octane see under AEM, #1 2-Amino-1-(3,4,5-trimethoxyphenyl)pentane see under AEM, #1 2-Amino-1-(3,4,5-trimethoxyphenyl)propane see TMA, #157 2-Amino-1-(3,4,5-trimethoxyphenyl)undecane see under AEM, #l AMM see TMA, #157 Amphedoxamine see MDA, #100 Amphetamine see under PEA, #142 and under 4-MA, #97 4-(n)-Amyl-2,5-dimethoxyamphetamine see DOAM, #61 Amylescaline see under B, #10 N-Amyi-MDA see under MDBZ, #103 a-Amylmescaline see under AEM, #1 N-(n)-Amyl-3,4-methylenedioxyamphetamine see under MDBZ, #103 4-(n)-Amyloxy-2,5-dimethoxyamphetamine see under MPM, #138 4-(n)-Amyloxy-3,5-dimethoxyamphetamine see under B, #10 4-(n)-Amyloxy-2,5-dimethoxyphenethylamine see under B, #10 '¥-Analogues see under ARIADNE, #8 Anethole see under 4-MA, #97 Anise see under TMA, #157 ANM see under AEM, #I AOM see under AEM, #1

927

928

Apiole see under DMMDA, #58 Apiolin see under TMA, #157 APM see under AEM, #1 ARIADNE #8 page 475 Artemisia see under TMA, #157 Asaricin see under TMA, #157

PIHKAL- A Chemical Love Story

Asarone (a,B, and y)see under TMA, #157 ASB #9 page 480 ASM see under AEM, #1 4-Astito-2,5-dimethoxyphenethylamine see under 2C-I, #33 Asymbescaline see ASM, #9 AUM see under AEM, #1 B #10 page 484 Basil see under TMA, #157 Bay see under TMA, #157 BDB see J, #94 BEATRICE #11 page 486 Benzescaline see under PE, #141 1-(1,3-Benzodioxol-5-yl)-2-butanamine see J, #94 1-(1,3-Benzodioxol-5-yl)-2-ethanamine see MDPEA, #115 1-(1,3-Benzodioxol-5-yl)-2-hexanamine see under METHYL-K, #129 1-(1,3-Benzodioxol-5-yl)-2-pentanamine see under METHYL-K, #129 1-(1,3-Benzodioxol-5-yl)-2-propanamine see MDA, #100 Benzylamines see under PEA, #142 4-Benzyl-2,5-dimethoxyamphetamine see under DOAM, #61 N-Benzyl-2,5-dimethoxy-4-iodoamphetamine see under IDNNA, #90 N-Benzyl-2,5-dimethoxy-4-iodo-N-methylamphetamine see under IDNNA,

#90 N-Benzyl-3,4-methylenedioxyamphetamine see MDBZ, #103 N-Benzyl-MDA see MDBZ, #102 4-Benzyloxy-3,5-dimethoxyamphetamine see 3C-BZ, #21 4-Benzyloxy-3,5-dimethoxyphenethylamine see under PE, #141 N-Benzylpiperizine see under PEA, #142 BET A-D see B-D, #51 Beta-deuteromescaline see B-D, #51 Betel pepper see under TMA, #157 Beth State see under ALEPH-7, #7 2,5-bis-(methylthio)-4-methylamphetamine see BIS-TOM, #12 2,5-bis-(methylthio)-4-methylphenethylamine see under BIS-TOM, #12 BIS-TOM #12 page 487 BL-3912 see ARIADNE, #8 BOAD see under BOHD, #16 BOB #13 page 490


BOD #14 page 492 BOED see under BOD, #14 BOH #15 page 496 BOHD #16 page 498 BOHH see under DME, #57 BOM #17 page 500 2-BR-3,5-DMA see under META-DOB, #124 2-BR-4,5-DMA see under META-DOB, #124 3-BR-2,6-DMA see under MET A-DOB, #124 4-BR-2,5-DMA see DOB, #62 4-BR-3,5-DMA #18 page 501

. 5-BR-2,3-DMA see under META-DOB, #124 5-BR-2,4-DMA see META-DOB, #124 6-BR-2,3-DMA see under MET A-DOB, #124 6-BR-DMPEA see under 2C-B, #20 3-BR-2,6-DNNA see under 3,4-DMA, #55 2-BR-4,5-MDA #19 page 502 6-BR-3,4-MDA see 2-BR-4,5-MDA, #19 4-Bromo-2,5-diethoxyphenethylamine see under 2C-B, #20 2-Bromo-3,5-dimethoxyamphetamine see under META-DOB, #124 2-Bromo-4,5-dimethoxyamphetamine see under 2C-B, #20 3-Bromo-2,6-dimethoxyamphetamine see under META-DOB, #124 4-Bromo-2,5-dimethoxyamphetamine see DOB, #62 4-Bromo-3,5-dimethoxyamphetamine see 4-BR-3,5-DMA, #18 5-Bromo-2,3-dimethoxyamphetamine see under META-DOB, #124 5-Bromo-2,4-dimethoxyamphetamine see META-DOB, #124 6-Bromo-2,3-dimethoxyamphetamine see under META-DOB, #124 3-Bromo-2,6-dimethoxy-N,N-dimethylamphetamine see under 3,4- DMA, #55 4-Bromo-2,5-dimethoxy-N-methylamphetamine see METHYL-DOB, #127 2-Bromo-4,5-dimethoxy-N-methylphenethylamine see under 2C-B, #20 2-Bromo-4,5-dimethoxyphenethylamine see under 2C-B, #20 4-Bromo-2,5-dimethoxyphenethylamine see 2C-B, #20 4-Bromo-3,5-dimethoxyphenethylamine see under DESOXY, #52 4-Bromo-2-ethoxy-5-methoxyphenethylamine see under 2C-B, #20 2-Bromo-4,5-methylenedioxyamphetamine see 2-BR-4,5-MDA, #19 4-(4-Bromophenylthio)-2,5-dimethoxyphenethylamine see under 2C- T-9, #45 4-Bromo-2,5,8-trimethoxyphenethylamine see BOB, #13 Buscaline see B, #10 4-(n)-Butoxy-2,5-dimethoxyamphetamine see under MPM, #138 4-(n)-Butoxy-3,5-dimethoxyamphetamine see under B, #10 4-(n)-Butoxy-2,5-dimethoxyphenethylamine see under 2C-0-4, #35 4-(n)-Butoxy-3,5-dimethoxyphenethylamine see B, #10 2-(n)-Butoxy-N,N-dimethyl-4-methoxyamphetamine see under 2,4- DMA, #53

929


N-(t)-Butylamino-MDA see under MDBZ, #102 N-(t)-Butylamino-3,4-methylenedioxyamphetamine see under MDBZ, #102 N-Butylamphetamine see under MDBU, #102 4-(i)-Buty1-2,5-dimethoxyamphetamine see under DOBU, #63 4-(n)-Buty1-2,5-dimethoxyamphetamine see DOBU, #63 4-(s)-Butyl-2,5-dimethoxyamphetamine see under DOBU, #63 4-(t)-Butyl-2,5-dimethoxyamphetamine see under DOBU, #63 N-Butyl-MDA see MDBU, #102 a-Butylmescaline see under AEM, #1 N-(i)-Butyl-3,4-methylenedioxyamphetamine see under MDBZ, #103 N-(n)-Butyl-3,4-methylenedioxyamphetamine see MDBU, #102 N-(t)-Butyl-3,4-methylenedioxyamphetamine see under MDBZ, #103 4-(t)-Butyl-thioanisole see under TOMSO, #173 4-(t)-Butylthio-2,5-dimethoxyamphetamine see under 2C-T-9, #45 4-(n)-Butylthio-3,5-dimethoxyamphetamine see under TP, #174 4-(s)-Butylthio-2,5-dimethoxy-N-hydroxyphenethylamine see HOT-17, #89 4-(n)-Butylthio-2,5-dimethoxyphenethylamine see under 2C-T -21, #49 4-(s)-Butylthio-2,5-dimethoxyphenethylamine see 2C-T -17, #48 4-(t)-Butylthio-2,5-dimethoxyphenethylamine see 2C-T-9, #45 4-(n)-Butylthio-3,5-dimethoxyphenethylamine see TB, #49 BZ see under PE, #141 2C-2 see under MMDA-2, #133 4C-2 see under MMDA-2, #133 2C-A see under 2C-I, #33 2C-3a see under MMDA-3a, #134 3C-A see under B, #10 4C-3a see under MMDA-3a, #134 3C-AL see under AL, #2 Calamol see under TMA, #157 Calamus see under TMA, #157 Camphor see underTMA, #157 4-Carboxy-2,5-dimethoxyphenethylamine see under 2C-C, #22 Carpacin see under TMA, #157 2C-B #20 page 503 3C-B see under B, #10 2CB-2,5-DIETO see under 2C-B, #20 2CB-2-ETO see under 2C-B, #20 2C-BIS-TOM see under BIS-TOM, #12 3C-BZ #21 page 507 2C-C #22 page 509 2C-CN see under 2C-C, #22 2C-COOH see under 2C-C, #22 3C-CPM see under CPM, #37


2C-D #23 page 511 2CD-2,5-DIETO see under 2C-D, #23 2CD-2-ETO see under 2C-D, #23 2CD-5-ETO see under 2C-D, #23 4C-DOM see ARIADNE, #8 2C-E #24 page 515 3C-E #25 page 519 2CE-5ETO see under 2C-E, #24 2C-EF see under DOEF, #64 2C-F #26 page 521 3C-FBZ see under 3C-BZ, #21 2C-G #27 page 522 2C-G-2 see under 2C-G-3, #28 2C-G-3 #28 page 526 2C-G-4 #29 page 529 2C-G-5 #30 page 532 2C-G-6 see under 2C-G-5, #30 2C-G-12 see under GANESHA, #85 2C-G-21 see under GANESHA, #85 2C-G-22 see under GANESHA, #85 2C-G-N #31 page 535 2C-H #32 page 537 3C-H see under B, #10 CHARMIAN see under ARIADNE, #8 Chavibetol see underTMA, #157 4-Chloro-2,5-dimethoxyamphetamine see DOC, #64 4-Chloro-2,5-dimethoxyphenethylamine see 2C-C, #22 4-Chlorophenethylamine see under PEA, #142 2C-I #33 page 539 2CI-2ETO see under 2C-I, #33 Cinnamon see under TMA, #157 3C-IP see under IP, #92 Citronella see underTMA, #157 Classic Ladies see under ARIADNE, #8 Clove see under TMA, #157 4-CL-PEA see under PEA, #142 2C-MMDA-4 see under TMA-4, #160 2C-N #34 page 542 2C-0-2 see under 2C-0-4, #35 2C-0-4 #35 page 543 2C-0-7 see under 2C-0-4, #35 2C-0-19 see under 2C-0-4. #35 Coconut see under TMA, #157

931

932

2C-P #36 page 545 3C-P see under P, #140 CPM #37 page 548 2C-PO see under 2C-SE, #38 Croweasin see under TMA, #157 3C-S see under B, #10 2C-SE #38 page 551 2C-SE-2 see under 2C-SE, #38 2C-SE-4 see under 2C-SE, #38 2C-SE-7 see under 2C-SE, #38 2C-SE-21 see under 2C-SE, #38 2C-T #39 page 554 2C-T -2 #40 page 557 2C-T-3 see under ALEPH-2, #4 2C-T-4 #41 page 561 \I'-2C-T-4 #42 page 564 2C-T-5 see under ALEPH-2, #4 2C-T-6 see under ALEPH-6, #6 2C-T-7 #43 page 567 2C-T-8 #44 page 571 2C-T -9 #45 page 573 2C-T-10 see under 2C-T-9, #45 2C-T-11 see under 2C-T-9, #45 2C-T-12 see under 2C-T-9, #45 2C-T-13 #46 page 576 2C-T-14 seeunder2C-T-13,#46 2C-T-15 #47 page 579 2C-T-16 see under ALEPH-2, #4 2C-T-17 #48 page 583 2C-T-18 see under 2C-T-15, #47 2C-T-19 see under 2C-T-21, #49 2C-T-20 see under ALEPH-2, #4 2C-T-21 #49 page 586 2C-T-21.5 see under 2C-T-21 2C-T-22 see under 2C-T-21, #49 2C-T-23 see under 2C-T-15, #47 3C-TB see underTM, #174 2C-TE see under 2C-SE, #38 2CT2-2,5-DIETO see under 2C-T-2, #40 2CT-2ETO see under 2C-T, #39 2CT2-2ETO see under 2C-T-2, #40 2CT2-5ETO see under 2C-T -2, #40 2CT4-2ETO see under 2C-T-4, #41



2CT-5ETO see under 2C-T, #39 2CT7-2ETO see under 2C-T-7, #43 3C-2-TIM see under 2-TIM, #152 3C-3-TIM see under 2-TIM, #152 3C-4-TIM see under 2-TIM, #152 3C-TM seeunderTP,#174 3C-3-TM see under 3-TM, #155 2C-TMA seeM, #96 2C-TMA-2 seeTMPEA, #168 2C-TMA-3 see underTMA-3, #159 2C-TMA-4 see underTMA-4, #160 2C-TMA-5 see underTMA-5, #161 2C-TMA-6 see underTMA-6, #162 2C-2-TOET see under 2-TOET, #169 2C-5-TOET see under 5-TOET, #170 2C-2-TOM see under 2-TOM, #171 2C-5-TOM see under 5-TOM, #172 2C-T -17 "R" see under 2C-T -17, #48 2C-T -17 "S" see under 2C-T -17, #48 4-Cyano-2,5-dimethoxyphenethylamine see under 2C-C, #22 N-Cyanomethyl-2,5-dimethoxy-4-iodoamphetamine see under lONNA, #90 N-Cyanomethyl-MDA see under MDBZ, #103 N-Cyanomethyl-3,4-methylenedioxyamphetamine see under MDBZ, #103 4-Cyclobutylthio-2,5-dimethoxyphenethylamine see under 2C-T -15, #4 7 4-Cyclohexylthio-2,5-dimethoxyamphetamine see under ALEPH-2, #4 4-Cyclohexylthio-2,5-dimethoxyphenethy1amine see under ALEPH-2, #4 and

under 2C-T-15,#47 4-Cyclopentylthio-2,5-dimethoxyphenethylamine see under 2C-T- 15, #47 Cyclopropylmescaline see CPM, #37 4-Cyclopropylmethoxy-3,5-dimethoxyamphetamine see under CPM, #37 4-Cyclopropylmethoxy-3,5-dimethoxyphenethylamine see CPM, #37 4-Cyclopropylmethyl-2,5-dimethoxyamphetamine see under DOBU, #63 N-Cyclopropylmethyl-2,5-dimethoxy-4-iodoamphetamine see under IDDNA,

#90 N-Cyclopropylmethyl-MDA see MDCPM, #104 N-Cyclopropylmethyl-3,4-methylenedioxyamphetamine see MDCPM, #104 4-Cyclopropylmethylthio-2,5-dimethoxyamphetamine see under 2C- T-8, #44 4-Cyclopropylmethylthio-2,5-dimethoxyphenethylamine see 2C-T -8, #44 4-Cyclopropylthio-2,5-dimethoxyphenethylamine see 2C-T -15, #47 2,6-D see under B-D, #51 3,5-D see under 4-D, #50 and under B-D, #51 4-D #SO page 590 a-D see under B-D, #51

933


8-D #51 page 592 DAPHNE see under ARIADNE, #8 2-(n)-Decyloxy-N,N-dimethyl-4-methoxyamphetamine see under 2,4- DMA,

#53 DEDMA see under IDNNA, #90 DESOXY #52 page 596 4-Desoxymescaline see DESOXY, #52 2,6-Deuteromescaline see under B-D, #51 3,5-Deuteromescaline see under 4-D, #50 and under 8-D, #51 4-Deuteromescaline see 4-D, #50 a-Deuteromescaline see under 8-D, #51 8-Deuteromescaline see 8-D, #51 3,5-Didesoxymescaline see under DESOXY, #52 a,a-Dideuteromescaline see under 8-D, #51 8,8-Dideuteromescaline see B-D, #51 2,6-Dideutero-3,4,5-trimethoxyphenethylamine see under 8-D, #51 a,a-Dideutero-3,4,5-trimethoxyphenethylamine see under B-D, #51 8,8-Dideutero-3,4,5-trimethoxyphenethylamine see 8-D, #51 2,4-Diethoxy-N,N-dimethylamphetamine see under 2,4-DMA, #53 3,4-Diethoxy-5-ethylthiophenethylamine see 3-T-TRIS, #178 3,5-Diethoxy-4-ethylthiophenethylamine see 4-T-TRIS, #179 2,4-Diethoxy-5-methoxyamphetamine see EEM, #74 2,5-Diethoxy-4-methoxyamphetamine see EME, #75 4,5-Diethoxy-4-methoxyamphetamine see MEE, 121 3,4-Diethoxy-5-methoxyphenethylamine see ASB, #9 3,5-Diethoxy-4-methoxyphenethylamine see SB, #144 2,5-Diethoxy-4-methylphenethylamine see under 2C-D, #23 2,5-Diethoxy-4-methylthiophenethylamine see under 2C-T -2, #40 3,4-Diethoxy-5-methylthiophenethylamine see 5-TASB, #148 3,5-Diethoxy-4-methylthiophenethylamine see 4-TSB, #177 4-Diethylaminothio-2,5-dimethoxyphenethylamine see under 2C-T- 9, #45 3,4-Diethyl-2,5-dimethoxyamphetamine see under GANESHA, #85 N,N-Diethyl-2,4-dimethoxyamphetamine see under 2,4-DMA, #53 N,N-Diethyl-2,5-dimethoxyamphetamine see under IDNNA, #90 N,N-Diethyl-2,5-dimethoxy-4-iodoamphetamine see under IDNNA, #90 3,4-Diethyl-2,5-dimethoxyphenethylamine see under GANESHA, #85 N,N-Diethyl-MDA see under MDBZ, #103 N,N-Diethyl-3,4-methylenedioxyamphetamine see under MDBZ, #103 4-(2,2-Difluoroethylthio)-2,5-dimethoxyphenethylamine see under 2C-T -21,

#49 2,8-Dihydroxy-4,5-dimethoxyphenethylamine see underTMA-2, #158 3,6-Dihydroxy-2-methoxy-4-methylamphetamine see under \f-DOM, #69 Dill see under TMA, #157


Dillapiole see under DMMDA-2, #59 2,5-Dimethoxy-4-acetamidoamphetamine see under DOC, #64 2,5-Dimethoxy-b-acetoxy-4-methylphenethylamine see under BOHD, #16 3,4-Dimethoxy-N-acetylphenethy1amine see under DMPEA, #60 3,5-Dimethoxy-4-ally1oxyamphetamine see under AL, #2 3,5-Dimethoxy-4-allyloxyphenethylamine see AL, #2 2,5-Dimethoxy-4-allylthiophenethylamine see under ALEPH-2, #4 2,5-Dimethoxy-4-aminoamphetamine see under DOC, #64 3,6-Dimethoxy-4-(2-aminoethyl)benzonorbomane see 2C-G-5, #30 4,7-Dimethoxy-5-(2-aminoethy1)indane see 2C-G-3, #28 5,8-Dimethoxy-6-(2-aminoethy1)tetralin see 2C-G-4, #29 3,6-Dimethoxy-4-(2-aminopropyl)benzonorbomane see G-5, #84 4,7-Dimethoxy-5-(2-aminopropyl)indane see G-3, #82 5,8-Dimethoxy-6-(2-aminopropyl)tetralin see G-4, #83 2,3-Dimethoxyamphetamine see under 3,4-DMA, #55 2,4-Dimethoxyamphetamine see 2,4-DMA, #53 2,5-Dimethoxyamphetamine see 2,5-DMA, #54 2,6-Dimethoxyamphetamine see under 3,4-DMA, #55 3,4-Dimethoxyamphetamine see 3,4-DMA, #55 3,5-Dimethoxyamphetamine see under 3,4-DMA, #55 2,5-Dimethoxy-4-(n)-amy1amphetamine see DOAM, #61 2,5-Dimethoxy-4-(n)-amy1oxyamphetamine see under MPM, #138 3,5-Dimethoxy-4-(n)-amyloxyamphetamine see under B, #10 3,4-Dimethoxy-4-(n)-amy1oxyphenethylamine see under B, #10 2,5-Dimethoxy-4-astitophenethy1amine see under 2C-I, #33 2,5-Dimethoxy-4-benzylamphetamine see under DOAM, #61 2,5-Dimethoxy-N-benzyl-4-iodoamphetamine see under IDNNA, #90 2,5-Dimethoxy-N-benzy1-4-iodo-N-methylamphetamine see under IDNNA,

#90 3,5-Dimethoxy-4-benzyloxyamphetamine see 3C-BZ, #21 3,5-Dimethoxy-4-benzy1oxyphenethy1amine see under PE, #141 2,3-Dimethoxy-5-bromoamphetamine see under META-DOB, #124 2,3-Dimethoxy-6-bromoamphetamine see under META-DOB, #124 2,4-Dimethoxy-5-bromoamphetamine see META-DOB, #124 2,5-Dimethoxy-4-bromoamphetamine see DOB, #62 2,6-Dimethoxy-3-bromoamphetamine see under META-DOB, #124 3,5-Dimethoxy-2-bromoamphetamine see under META-DOB, #124 3,5-Dimethoxy-4-bromoamphetamine see 4-BR-3,5-DMA, #18 4,5-Dimethoxy-2-bromoamphetamine see under META-DOB, #124 2,6-Dimethoxy-3-bromo-N,N-dimethylamphetamine see under 3,4- DMA, #55 2,5-Dimethoxy-4-bromo-N-methylamphetamine see METHYL-DOB, #127 4,5-Dimethoxy-2-bromo-N-methylphenethylamine see under 2C-B, #20 2,5-Dimethoxy-4-bromophenethylamine see 2C-B, #20

935


3,5-Dimethoxy-4-bromophenethylamine see under DESOXY, #52 4,5-Dimethoxy-2-bromophenethylamine see under 2C-B, #20 1-(2,5-Dimethoxy-4-bromophenyl)-2-aminobutane see under ARIADNE, #8 2,5-Dimethoxy-4-(4-bromophenylthio)phenethylamine see under 2C- T-9, #45 2,5-Dimethoxy-4-(n)-butoxyamphetamine see under MPM, #38 2,5-Dimethoxy-4-(n)-butoxyphenethylamine see under 2C-0-4, #35 3,5-Dimethoxy-4-(n)-butoxyphenethylamine see B, #10 2,5-Dimethoxy-4-(i)-butylamphetamine see under DOBV, #63 2,5-Dimethoxy-4-(n)-butylamphetamine see DOBU, #63 2,5-Dimethoxy-4-(s)-butylamphetamine see under DOBV, #63 2,5-Dimethoxy-4-(t)-butylamphetamine see under DOBV, #63 2,5-Dimethoxy-4-(t)-butylthioamphetamine see under 2C-T-9, #45 3,5-Dimethoxy-4-(n)-butylthioamphetamine see under TP, #174 2,5-Dimethoxy-(s)-butylthio-N-hydroxyphenethylamine see HOT -17, #89 2,5-Dimethoxy-4-(n)-butylthiophenethylamine see under 2C-T-21, #49 3,5-Dimethoxy-4-(n)-butylthiophenethylamine see TB, #149 2,5-Dimethoxy-4-( s )-butylthiophenethylamine see 2C-T -17, #48 2,5-Dimethoxy-4-(t)-butylthiophenethylamine see 2C-T -9, #45 2,5-Dimethoxy-4-earboxyphenethylamine see under 2C-C, #22 2,5-Dimethoxy-4-ehloroamphetamine see DOC, #64 2,5-Dimethoxy-4-ehlorophenethylamine see 2C-C, #22 2,5-Dimethoxy-N-eyanomethyl-4-iodoamphetamine see under IDNNA, #90 2,5-Dimethoxy-4-eyanophenethylamine see under 2C-C, #22 2,5-Dimethoxy -4-eyclobutylthiophenethy I amine see under 2C-T -15, #4 7 2,5-Dimethoxy-4-eyclohexylthioamphetamine see under ALEPH-2, #4 2,5-Dimethoxy-4-eyclohexylthiophenethylamine see under ALEPH-2, #4 and

under 2C-T-15, #47 2,5-Dimethoxy-4-eyclopenylthiophenethylamine see under 2C-T-15, #47 3,5-Dimethoxy-4-eyclopropylmethoxyamphetamine see under CPM, #37 3,5-Dimethoxy-4-eyclopropylmethoxyphenethylamine see CPM, #37 2,5-Dimethoxy-4-eyclopropylmethylamphetamine see under DOBV, #63 2,5-Dimethoxy-N-eyclopropylmethyl-4-iodoamphetamine see under IDNNA,

#90 2,5-Dimethoxy-N -eye lopropylmethyl-4-me thy }amphetamine see under

BEATRICE, #II 2,5-Dimethoxy-4-eyclopropylmethylthioamphetamine see under 2C- T-8, #44 2,5-Dimethoxy-4-eyclopropylmethylthiophenethylamine see 2C-T -8, #44 2,5-Dimethoxy-4-eyclopropylthiophenethylamine see 2C-T -15, #4 7 2,5-Dimethoxy-4-diethylaminothiophenethylamine see under 2C-T- 9, #45 2,4-Dimethoxy-N,N-diethylamphetamine see under 2,4-DMA, #53 2,5-Dimethoxy-3,4-diethylamphetamine see under GANESHA, #85 2,5-Dimethoxy-N,N-diethylamphetamine see under IDNNA, #90 2,5-Dimethoxy-N,N-diethyl-4-iodoamphetamine see IDNNA, #90


2,5-Dimethoxy-3,4-diethylphenethylamine see under GANESHA, #85 2,5-Dimethoxy-4-(2,2-difluoroethylthio )phenethylamine see under 2C-T -21,

#49 4,5-Dimethoxy-2,B-dihydroxyphenethylamine see under TMA-2, #158 2,5-Dimethox y-N -( 3-dimethy laminopropyl )-4-iodoamphetamine see under

IDNNA,#90 2,4-Dimethoxy-N,N-dimethylamphetamine see under 2,4-DMA, #53 2,5-Dimethoxy-3,4-dimethylamphetamine see GANESHA, #85 2,5-Dimethoxy-4,N-dimethylamphetamine see BEATRICE, #11 2,5-Dimethoxy-N,N-dimethylamphetamine see under 2,5-DMA, #54 2,6-Dimethoxy-N,N-dimethylamphetamine see under 3,4-DMA, #55 3,5-Dimethoxy-N,N-dimethylamphetamine see under 3,4-DMA, #55 2,5-Dimethoxy-4-(1,1-dimethylethyl)amphetamine see under DOBV, #63 2,4-Dimethoxy-N,N-dimethyl-5-fluoroamphetamine see under 2,4- DMA, #53 2,5-Dimethoxy-N,N-dimethyl-4-fluoroamphetamine see under 2,5- DMA, #54 2,4-Dimethoxy-N,N-dimethyl-5-iodoamphetamine see under 2,4-DMA, #53 2,5-Dimethoxy-N,N-dimethyl-4-iodoamphetamine see IDNNA, #90 2,6-Dimethoxy-N,N-dimethyl-3-iodoamphetamine see under 3,4-DMA, #55 2,5-Dimethoxy-3,4-dimethylphenethylamine see 2C-G, #27 2,5-Dimethoxy-N-dodecyl-4-iodoamphetamine see under IDNNA, #90 2,4-Dimethoxy-5-ethoxyamphetamine see MME, #136 2,5-Dimethoxy-4-ethoxyamphetamine see MEM, #122 3,5-Dimethoxy-4-ethoxyamphetamine see 3C-E, #25 4,5-Dimethoxy-2-ethoxyamphetamine see EMM, #76 2,5-Dimethoxy-B-ethoxy-4-methylphenethylamine see under BOD, #14 2,5-Dimethoxy-4-ethoxyphenethylamine see under 2C-0-4, #35 3,4-Dimethoxy-5-ethoxyphenethylamine see ME, #119 3,5-Dimethoxy-4-ethoxyphenethylamine see E, #72 2,4-Dimethoxy-N-ethylamphetamine see under 2,4-DMA, #53 2,5-Dimethoxy-4-ethylamphetamine see DOET, #66 2,5-Dimethoxy-3-ethyl-4-methylamphetamine see under GANESHA, #85 2,5-Dimethoxy-4-ethyl-3-methylamphetamine see under GANESHA, #85 2,5-Dimethoxy-3-ethyl-4-methylphenethylamine see under GANESHA, #85 2,5-Dimethoxy-4-ethyl-3-methylphenethylamine see under GANESHA, #85 2,5-Dimethoxy-4-ethylphenethylamine see 2C-E, #24 2,5-Dimethoxy-4-ethylthioamphetamine see ALEPH-2, #4 2,5-Dimethoxy-4-ethylthio-N-hydroxyphenethylamine see HOT-2, #87 2,5-Dimethoxy-4-ethylthiophenethylamine see 2C-T -2, #40 3,5-Dimethoxy-4-ethylthiophenethylamine see 4-TE, #151 4,5-Dimethoxy-3-ethylthiophenethylamine see 3-TME, #163 2,5-Dimethoxy-4-fluoroamphetamine see under 2C-F, #26 3,5-Dimethoxy-4-(4-fluorobenzyloxy)amphetamine see under 3C-BZ, #21 2,5-Dimethoxy-4-(2-fluoroethyl)amphetamine see DOEF, #65

937


2,5-Dimethoxy-4-(2-fluoroethyl)phenethylamine see under DOEF, #65 2,5-Dimethoxy-4-(2-fluoroethylseleneo)phenethylamine see under 2C-SE, #38 2,5-Dimethoxy-4-(2-fluoroethylthio )amphetamine see under 2C-T- 21, #49 2,5-Dimethoxy-4-(2-fluoroethylthio )phenethylamine see 2C-T -21, #49 2,5-Dimethoxy-4-fluorophenethylamine see 2C-F, #26 3,5-Dimethoxy-4-heptyloxyamphetamine see under B, #10 3,5-Dimethoxy-4-heptyloxyphenethylamine see under B, #10 2,4-Dimethoxy-N-(n)-hexylamphetamine see under 2,4-DMA, #53 2,5-Dimethoxy-4-(n)-hexylamphetamine see under DOAM, #61 2,5-Dimethoxy-N-(n)-hexyl-4-iodoamphetamine see under IDNNA, #90 3,5-Dimethoxy-4-hexyloxyamphetamine see under B, #10 3,5-Dimethoxy-4-hexy1oxyphenethy1amine see under B, #10 3,5-Dimethoxy-4-hydroxyamphetamine see underTMA, #157 2,5-Dimethoxy-4-(2-hydroxyethyl)amphetamine see under DOEF, #65 2,5-Dimethoxy-B-hydroxy-4-methylphenethylamine see BOHD, #16 3,4-Dimethoxy-B-hydroxyphenethy1amine see DME, #57 2,5-Dimethoxy-4-( 1-hydroxypropyl)amphetamine see under DOPR, #71 2,5-Dimethoxy-N-hydroxy-4-(n)-propylthiophenethylamine see HOT- 7, #88 2,5-Dimethoxy-4-iodoamphetamine see DOl, #67 2,5-Dimethoxy-4-iodo-N-methylamphetamine see under IDNNA, #90 2,5-Dimethoxy-4-iodo-N-methyl-N-(i)-propylamphetamine see under IDNNA,

#90 2,5-Dimethoxy-4-iodophenethylamine see 2C-I, #33 2,5-Dimethoxy-4-iodo-N-(i)-propylamphetamine see under IDNNA, #90 2,5-Dimethoxy-4-(2-methoxyethylthio )phenethylamine see 2C-T -13, #46 3,5-Dimethoxy-4-(2-methoxyethoxy)phenethylamine see under MAL, #99 3,5-Dimethoxy-4-methallyloxyphenethylamine see MAL, #99 2,5-Dimethoxy-4-methallylthioamphetamine see under ALEPH-2, #4 2,5-Dimethoxy-4-methallylthiophenethylamine see under ALEPH-2, #4 2,4-Dimethoxy-5-methylamphetamine see under DOM, #68 2,4-Dimethoxy-N-methylamphetamine see under 2,4-DMA, #53 2,4-Dimethoxy-6-methylamphetamine see under '1'-DOM, #69 2,5-Dimethoxy-4-methylamphetamine see DOM, #68 2,5-Dimethoxy-N-methylamphetamine see METHYL-DMA, #26 2,6-Dimethoxy-4-methylamphetamine see '1'-DOM, #69 4,5-Dimethoxy-2-methylamphetamine see under DOM, #68 N-(2,5-Dimethoxy-4-methylbenzyl)piperazine see under PEA, #142 2,3-Dimethoxy-4,5-methylenedioxyamphetamine see DMMDA-2, #59 2,5-Dimethoxy-3,4-methylenedioxyamphetamine see DMMDA, #58 2,5-Dimethoxy-N-methyl-3,4-methylenedioxyamphetamine see under

METHYL-MMDA-2, #131 2,5-Dimethoxy-B-methyl-3,4-methylenedioxyamphetamine see under

DMMDA,#58


2,5-Dimethoxy-3,4-methylenedioxymethamphetamine see under METHYLMMDA-2, #131

2-(2,5-Dimethoxy-3,4-methylenedioxyphenyl)-3-aminobutane see under DMMDA,#58

2,5-Dimethoxy-4-methylphenethylamine see 2C-D, #23 3,5-Dimethoxy-4-methylphenethylamine see DESOXY, #52 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminobutane see ARIADNE, #8 2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine see DMCPA, #56 2-(2,5-Dimethoxy-4-methylphenyl)ethanolamine see BOHD, #16 1-(2,5-Dimethoxy-4-methyl)-2-hydroxylaminobutane see under ARIADNE, #8 2,5-Dimethoxy-4-(1-methylpropyl)-amphetamine see under DOBU, #63 2,5-Dimethoxy-4-(2-methylpropyl)-amphetamine see under DOBU, #63 2,5-Dimethoxy-4-methylpoloniophenethylamine see under 2C-SE, #38 2,5-Dimethoxy-4-methylselenophenethylamine see 2C-SE, #38 2,5-Dimethoxy-4-methyltelluriophenethylamine see under 2C-SE, #38 2,3-Dimethoxy-4-methylthioamphetamine see under 2-TIM, #152 2,4-Dimethoxy-3-methylthioamphetamine see under 2-TIM, #152 2,4-Dimethoxy-5-methylthioamphetamine see META-DOT, #125 2,5-Dimethoxy-4-methylthioamphetamine see ALEPH-I, #3 3,4-Dimethoxy-2-methylthioamphetamine see under 2-TIM, #152 3,4-Dimethoxy-5-methylthioamphetamine see under 3-TM, #155 3,5-Dimethoxy-4-methylthioamphetamine see under TP, #174 4,5-Dimethoxy-2-methylthioamphetamine see ORTHO-DOT, #139 2,5-Dimethoxy-4-(2-methylthioethylthio )phenethylamine see under 2C-T -13,

#46 2,3-Dimethoxy-4-methylthiophenethylamine see 4-TIM, #154 2,4-Dimethoxy-3-methylthiophenethylamine see 3-TIM, #153 2,5-Dimethoxy-4-methylthiophenethylamine see 2C-T, #39 3,4-Dimethoxy-2-methylthiophenethylamine see 2-TIM, #152 3,4-Dimethoxy-5-methylthiophenethylamine see 3-TM, #155 3,5-Dimethoxy-4-methylthiophenethylamine see TM, #156 2,5-Dimethoxy-4-methyltranylcypromine see DMCPA, #56 2,5-Dimethoxy-4-(N-morpholinylthio)-phenethylamine see under 2C-T-9, #45 1,4-Dimethoxy-2-naphthylethylamine see 2C-G-N, #31 1,4-Dimethoxy-2-naphthylisopropylamine see G-N, #86 2,5-Dimethoxy-4-nitroamphetamine see DON, #70 2,5-Dimethoxy-4-nitrophenethylamine see 2C-N, #34 2,5-Dimethoxyphenethylamine see 2C-H, #32 3,4-Dimethoxyphenethylamine see DMPEA, #60 3,5-Dimethoxy-4-phenethyloxyphenethylamine see PE, #141 3,4-Dimethoxyphenylacetic acid see under DMPEA, #60 l-(2,5-Dimethoxyphenyl)-2-aminobutane see under ARIADNE, #8 1-(3,4-Dimethoxypheny1)-2-aminobutane see under ARIADNE, #8

939


1-(2,4-Dimethoxyphenyl)-2-(N,N-dimethylamino )butane see under ARIADNE,#8

1-(2,5-Dimethoxy-4-bromophenyl)-2-aminobutane see under ARIADNE, #8 1-(2,5-Dimethoxyphenyl)-2-(N ,N-dimethylamino )butane see under

ARIADNE,#8 1-(3 ,5-Dimethox ypheny I)-2-(N ,N -dime thy lamino )butane see under

ARIADNE,#8 2-(3,4-Dimethoxyphenyl)-2-ethanolamine see DME, #57 1-(2,5-Dimethoxyphenyl-4-iodo)-2-aminobutane see under DOl, #67 2,5-Dimethoxy-4-phenylthioamphetamine see ALEPH-6, #6 2,5-Dimethoxy-4-phenylthiophenethylamine see under ALEPH-6, #6 2,5-Dimethoxy-4-(i)-propoxyamphetamine see under MPM, #138 2,5-Dimethoxy-4-(n)-propoxyamphetamine see MPM, #138 3,5-Dimethoxy-4-(n)-propoxyamphetamine see under P, #140 2,5-Dimethoxy-4-(i)-propoxyphenethylamine see 2C-0-4, #35 2,5-Dimethoxy-4-(n)-propoxyphenethylamine see under 2C-0-4, #35 3,4-Dimethoxy-5-(i)-propoxyphenethylamine see under MP, #137 3,4-Dimethoxy-5-(n)-propoxyphenethylamine see MP, #137 3,5-Dimethoxy-4-(i)-propoxyphenethylamine see IP, #92 3,5-Dimethoxy-4-(n)-propoxyphenethylamine seeP, #140 2,4-Dimethoxy-N-(i)-propylamphetamine see under 2,4-DMA, #53 2,4-Dimethoxy-N-(n)-propylamphetamine see under 2,4-DMA, #53 2,5-Dimethoxy-4-(i)-propylamphetamine see under DOPR, #71 2,5-Dimethoxy-4-(n)-propylamphetamine see DOPR, #71 3,5-Dimethoxy-4-(i)-propylamphetamine see under IP, #92 2,5-Dimethoxy-4-(n)-propylphenethylamine see 2C-P, #36 2,5-Dimethoxy-4-(i)-propylselenophenethylamine see under 2C-SE, #38 2,5-Dimethoxy-4-(n)-propylselenophenethylamine see under 2C-SE, #38 2,5-Dimethoxy-4-(i)-propylthioamphetamine see ALEPH-4, #5 2,5-Dimethoxy-4-(n)-propylthioamphetamine see ALEPH-7, #7 2,5-Dimethoxy-4-(n)-propylthio-N-methylphenethylamine see under 2C-T -7,

#43 2,5-Dimethoxy-4-(i)-propylthiophenethylamine see 2C-T-4, #41 2,5-Dimethoxy-4-(n)-propylthiophenethylamine see 2C-T-7, #43 2,6-Dimethoxy-4-(i)-propylthiophenethylamine see 'P-2C-T-4, #42 3,5-Dimethoxy-4-(n)-propylthiophenethylamine see TP, #174 3,5-Dimethoxy-4-(2-propynyloxy)phenethylamine see PROPYNYL, #143 2,5-Dimethoxy-4-(2-pyridinylthio)-phenethylamine see under 2C- T-9, #45 2,5-Dimethoxy-3,4-(tetramethylene)amphetamine see G-4, #83 2,5-Dimethoxy-3,4-(tetramethylene)phenethylamine see 2C-G-4, #29 3,5-Dimethoxy-4-trideuteromethoxyphenethylamine see 4-D, #50 2,5-Dimethoxy-4-(2,2,2-trifluoroethylthio )phenethylamine see under 2C-T -21,

#49


2,5-Dimethoxy-3,4-(trimethylene)amphetamine see G-3, #82 2,5-Dimethoxy-3,4-(trimethylene)phenethylamine see 2C-G-3, #28 7 -[2-(N,N-dimethylamino )propyl]-5-iodo-4-methoxyindane see under 2C-G-3,

#28 7-[2-(N,N-dimethylamino)propylj-4-methoxyindane see under 2C-G- 3, #28 2,5-Dimethylamphetamine see under 2,4-DMA, #54 3,4-Dimethylamphetamine see under 2,4-DMA, #54 N,N-Dimethylamphetamine see under PEA, #142 N,N-Dimethyl-2,4-di-(i)-propoxyamphetamine see under 2,4-DMA, #54 N,N-Dimethyl-2-ethoxy-4-methoxyamphetamine see under 2,4-DMA, #54 N,N-Dimethyl-5-iodo-4-methoxy-2,3-trimethyleneamphetamine see under 2C-

G-3, #28 N,N-Dimethyl-MDA see MDDM, #105 N,N-Dimethylmescaline see under M, #96 N,N-Dimethyl-2-methoxyamphetamine see METYHL-MA, #130 N,N-Dimethyl-4-methoxyamphetamine see METYHL-MA, #130 3,5-Dimethyl-4-methoxyphenethylamine see under DESOXY, #52 N,N-Dimethyl-4-methoxy-2,3-(trimethylene)amphetamine see under 2C-G-3,

#28 2,N-Dimethyl-4,5-methylenedioxyamphetamine see MADAM-6, #98 4,N-Dimethyl-2,3-methylenedioxyamphetamine see under MADAM-6, #98 N,N-Dimethyl-3,4-methylenedioxyamphetamine see MDDM, #105 a.,a.-Dimethyl-3,4-methylenedioxyphenethylamine see MDPH, #116 N,N-Dimethyl-2-(3,4,5-trimethyloxyphenoxy)ethylamine see under M, #96 N,N-Dimethyl-3,4,5-trimethoxyphenylamine see under M, #96 Dimoxamine see ARIADNE, #8 DMA see 2,5-DMA, #54 2,3-DMA see under 3,4-DMA, #55 2,4-DMA #53 page 599 2,5-DMA #54 page 601 2,6-DMA see under 3,4-DMA, #55 3,4-DMA #55 page 604 3,5-DMA see under 3,4-DMA, #55 DMCPA #56 page 607 DMDOI see under 2,4-DMA, #53 DME #57 page 609 DMMA see METHYL-DMA, #126 DMMDA #58 page 610 DMMDA-2 #59 page 613 DMMDMA see under METHYL-MMDA-2, #131 2,5-DMNNA see under 2,5-DMA, #54 DMPEA #60 page 614 DNNA see under 2,5-DMA, #54

941

942

2,4-DNNA see under 2,4-DMA, #53 2,6-DNNA see under 3,4-DMA, #55 3,5-DNNA see under 3,4-DMA, #55 DOA see under DOC, #64 DOAA see under DOC, #64 DOAM #61 page 617 DOB #62 page 620 DOBU #63 page 622 DOBZ see under DOAM, #61 DOC #64 page 626 DOCPM see under DOBU, #63 DOEF #65 page 628 DOEH see under DOEF, #65 DOET #66 page 631 DOF see under 2C-F, #26 DOHE see under DOAM, #61 DOl #67 page 633 DOIB see under DOBV, #63 DOIP see under DOPR, #71 DOM #68 page 637 '1'-DOM #69 page 643 DOM-AI see under PEA, #142 DOM-AT see under PEA, #142 DON #70 page 646 DOONE see METHYL-MA, #130 DOPR #71 page 647 DOSB see under DOBV, #63 DOT see ALEPH, #3 DOTB see under DOBV, #63 E #72 page 650 4-EA see under4-MA, #97 EA-1297 see MDPEA, #115 EA-1298 see MDA, #100 EA-1302 see under PEA, #142 EA-1306 see M, #96 EA-1316 see 3,4-DMA, #55 EA-1319 see TMA, #157 EA-1322 see under ARIADNE, #8 Ecstasy see MDMA, #109 EDA see under MDA, #1 00 EDEN see METHYL-J, #128 EDMA see MDMC, #110 EEE #73 page 654



EEM #74 page 656 Elemi see underTMA, #157 Elemicin see under TMA, #157 ELVIRA see under ARIADNE, #8 EMDA-2 see under MMDA-2, #133 EME #75 page 658 EMM #76 page 659 Escaline see E, #72 Esdragol see under 4-MA, #97 Essential Amphetamines see under TMA, #157 Essential Oils see under TMA, #157 Estragole see under 4-MA, #97 Eternity see under 2C-E, #24 4-Ethoxyamphetamine see under 4-MA, #97 5-Ethoxy-4-ethyl-2-methoxyphenethylamine see under 2C-E, #24 2-Ethoxy-4-ethylthio-5-methoxyphenethylamine see under 2C-T-2, #40 3-Ethoxy-4-ethylthio-5-methoxyphenethylamine see 4-TASB, #147 3-Ethoxy-5-ethylthio-4-methoxyphenethy1amine see 3-TSB, #176 4-Ethoxy-3-ethy1thio-5-methoxyphenethylamine see 3-TASB, #146 5-Ethoxy-4-ethylthio-5-methoxyphenethylamine see under 2C-T-2, #40 2-Ethoxy-4-iodo-5-methoxyphenethy1amine see under 2C-I, #33 4-Ethoxy-3-methoxyamphetamine see under MEPEA, #123 5-Ethoxy-2-methoxy-4-methylamphetamine see IRIS, #93 2-Ethoxy-5-methoxy-4-methy1phenethy1amine see under 2C-D, #23 5-Ethoxy-2-methoxy-4-methy1phenethy1amine see under 2C-D, #23 2-Ethoxy-5-methoxy-4-methylthiophenethy1amine see under 2C-T, #39 3-Ethoxy-4-methoxy-5-methy1thiophenethy1amine see 5-TME, #165 3-Ethox y-5-methox y -4-methylthiophenethy 1amine see 4-TME, # 164 4-Ethoxy-5-methoxy-3-methy1thiophenethy1amine see 3-TE, #150 5-Ethoxy-2-methoxy-4-methylthiophenethylamine see under 2C-T, #23 4-Ethoxy-3-methoxyphenethylamine see MEPEA, #123 2-Ethoxy-5-methoxy-4-(i)-propylthiophenethy1amine see under 2C- T-4, #41 2-Ethoxy-5-methoxy-4-(n)-propylthiophenethy1amine see under 2C- T-7, #43 2-Ethoxy-4,5-methylenedioxyamphetamine see under MMDA-2, #133 2-Ethy1amino-1-(3,4-methy1enedioxypheny1)butane see ETHYL-J, #77 2-Ethy1amino-1-(3,4-methy1enedioxypheny1)hexane see under METHYL-K

#129 2-Ethy1amino-1-(3,4-methy1enedioxypheny1)pentane see ETHYL-K, #78 N-Ethy1amphetamine see under MDBU, #102 N-Ethy1-1-( 1 ,3-benzodioxo1-5-y1)-2-butanamine see ETHYL-J, #77 N-Ethy1-1-( 1 ,3-benzodioxol-5-yl)-2-hexanamine see under METHYL-K N-Ethyl-1-(1 ,3-benzodioxol-5-yl)-2-pentanamine see ETHYL-K, #78 3,4-Ethylenedioxy-5-methoxyamphetamine see MEDA, #120

943


3,4-Ethylenedioxy-N-methylamphetamine see MDMC, #110 ETHYL-I see MDE, #106 ETHYL-J #77 page 662 ETHYL-K #78 page 663 ETHYL-L see under METHYL-K, #129 ETHYL-MDA see MDE, #106 a-Ethylmescaline see AEM, #1 4-Ethyl-2-methoxy-5-methylthioamphetamine see 5-TOET, #170 4-Ethyl-5-methoxy-2-methylthioamphetamine see 2-TOET, #169 4-Ethyl-2-methoxy-5-methylthiophenethylamine see under 5-TOET, #170 4-Ethyl-5-methoxy-2-methylthiophenethylamine see under 2-TOET, #169 N-Ethyl-3,4-methylenedioxyamphetamine see MDE, #106 a-Ethyl-3,4-methylenedioxybenzylamine see under MDA, #100 a-Ethyl-N-methyl-3,4-methylenedioxybenzylamine see under MDA, #100 N-Ethyl-1-(3,4-methylenedioxyphenyl)-2-aminobutane see ETHYL-J, #77 N-Ethyl-1-(3,4-methylenedioxyphenyl)-2-aminohexane see under METHYL-

K, #129 N-Ethyl-1-(3,4-methylenedioxyphenyl)-2-aminopentane see ETHYL-K, #78 Euasarone see under TMA-2, # 158 Eugenol see under TMA, #157 EVE see MDE, #106 F see under F-2, #79 F-2 #79 page 664 F -22 #80 page 667 F-23 see under F-22, #80 F-233 see under F-22, #80 F-31 0 see under DOM, #68 F-320 see under DOM, #68 Fennel see under TMA, #157 FDNNA see under 2,5-DMA, #54 FLADAM see under FLEA, #81 FLEA #81 page 671 FLORENCE see under ARIADNE, #8 2-Fluoro-4,5-methylenedioxyamphetamine see under FLEA, #81 N-Formyl-MDA see under MDMA, #109 N-Formyl-3,4-methylenedioxyamphetamine see under MDMA, #109 G see GANESHA, #85 G-2 see under 2C-G-3, #28 G-3 #82 page 674 G-4 #83 page 676 G-5 #84 page 676 G-6 see under G-5, #84 G-12 see underGANESHA, #85


G-21 see under GANESHA, #85 G-22 see under GANESHA, #85 GAMMA see under MDA, #100 GANESHA #85 page 678 Ginger see under TMA, #157 G-N #86 681 Green Apiol see under TMA, #157 H see MDPEA, #115 HADAM see FLEA, #81 Hardinamine see under 2C-SE, #38 HECATE see DOET, #66 Heptescaline see under B, #10 N-Heptyl-MDA see under MDBZ, #103 a-Heptylmescaline see under AEM, #1 N-(4-Heptyl)-3,4-methylenedioxyamphetamine see under MDBZ, #103 Hexescaline see under B, #10 N-Hexyl-MDA see under MDBZ, #103 a-Hexylmescaline see under AEM, #1 N-(n)-Hexyl-3,4-methylenedioxyamphetamine see under MDBZ, #103 Homopiperonylamine see MDPEA, #115 HOT-2 #87 page 682 HOT-7 #88 page 683 HOT-17 #89 page 685 4-Hydroxyamphetamine see under 4-MA, #97 B-Hydroxy-2C-D see BOHD, #16 Hydroxy-DOPR see under DOPR, #71 N-Hydroxyethyl-MDA see MDHOET, #107 N-(2-Hydroxyethyl)-3,4-methylenedioxyamphetamine see MDHOET, #107 N-Hydroxy-MDA see MDOH, #114 N-Hydroxy-MDMA see FLEA, #81 4-Hydroxy-3-methoxyamphetamine see under MEPEA, #123 5-Hydroxy-2-methoxy-N-methylamphetamine see under METHYL-DMA,

#126 N-Hydroxy-3,4-methylenedioxyamphetamine see MDOH, #114 B-Hydroxy-3,4-methylenedioxyphenethylamine see under DME, #57 N-Hydroxy-N-methyl-3,4-methylenedioxyamphetamine see FLEA, #81 I see MDA, #100 IDA see under MDA, #100 IDNNA #90 page 687 IM #91 page 690 Indian-root see under TMA, #157 IP #92 page 692 IRIS #93 page 694

945

946

Isoapiole see under DMMDA, #58 lsodillapiole see under DMMDA-2, #59 Isoelemicin see under TMA, #157 lsoeugenol see under TMA, #157 Isomescaline see IM, #91 Isomyristicin see under MMDA, #132 lsoosmorrhizole see under TMA, #157 Isopropyl-MDA see MDIP, #108 Isoproscaline see IP, #92 Isosafrole see under MDA, #100 J #94 page 698 Jacobamine see J, #94 JUNO see under ARIADNE, #8 K see under METHYL-K, #129 L see under METHYL-K, #129 Laurel see under TMA, #157 LE-25 see 2C-D, #23 LOPHOPHINE #95 page 701 M #96 page 702 2-MA see under4-MA, #97 3-MA see under4-MA, #97 4-MA #97 page 707 Mace see underTMA, #157 MAD see under MAL, #99 MADAM-2 see under MADAM-6, #98 MADAM-6 #98 page 709 MAL #99 page 712 M-ALPHA see under MDA, #100 MAM see under MPM, #138 MAPEA see under MEPEA, #123 Mauve Spot see under DMPEA, #60 MBDB see METHYL-J, #128 MBM see under MPM, # 138 MDA #100 page 714 MDAL #101 page 719 MDAM see under MDBZ, #103 MDBA see under MDBZ, #103 MDBU #102 page 720 MDBZ #103 page 721 MDCF3 see under MDE, #106 MDCM see underMDBZ, #103 MDCN see under MDBZ, #103 MDCPM #104 page 724

PIHKAL - A Chemical Love Story


MDDE see under MDBZ, #103 MDDM #105 page 725 MDE #106 page 727 MDHE see under MDBZ, #103 MDEA see MDE, #106 MDHOET #107 page 731 MDHE see under MDBZ, #103 MDIB see under MDBZ, #103 MDIP #108 page 732 MDM seeMDMA,#109 MDMA #109 page 733 MDMC #110 page 739 MDMEO #111 page 741 MDMEOET #112 page 742 MDMP #113 page 743 MDOC see under MDBZ, #103 MDOH #114 page 744 MDPEA #115 page 747 MDPH #116 page 748 MDPL #117 page 752 MDPR #118 page 753 MDSE see under MDBZ, #103 MDTB see under MDBZ, #103 ME #119 page 755 MEDA #120 page 759 MEE #121 page 761 MEM #122 page 764 MEPEA #123 page 769 Mescaline see M, #96 META-DOB #124 page 771 META-DOT #125 page 772 Metaescaline see ME, #119 Metaisoproscaline see under MP, #137 Metaproscaline see MP, #137 4-Methallyldesmethoxymescaline see MAL, #99 Methallylescaline see MAL, #99 4-Methallylthio-2,5-dimethoxyamphetamine see under ALEPH-2, #4 4-Methallylthio-2,5-dimethoxyphenethylamine see under ALEPH-2, #4 Methamphetamine see under PEA, #142 and under MDBU, #102 3-Methoxy-4-allyloxyamphetamine see under MEPEA, #123 3-Methoxy-4-allyloxyphenethylamine see under MEPEA, #123 2-Methoxyamphetamine see under 4-MA, #97 3-Methoxyamphetamine see under 4-MA, #97

947

948 PIHKAL - A Chemical Love Story

4-Methoxyamphetamine see 4-MA, #97 B-Methoxy-2C-B see BOB, #13 B-Methoxy-2C-D see BOD, #14 2-Methoxy-4,5-diethoxyamphetamine see MEE, #121 4-Methoxy-2,5-diethoxyamphetamine see EME, #75 5-Methoxy-2,4-diethoxyamphetamine see EEM, #74 N-Methoxy-MDA see MDMEO, #Ill 3-Methoxy-4-ethoxyamphetamine see under MEPEA, #123 5-Methoxy-3-ethoxy-4-ethylthiophenethylamine see 4-TASB, #147 5-Methoxy-4-ethoxy-3-ethylthiophenethylamine see 3-TASB, #146 2-Methoxy-5-ethoxy-4-methylamphetamine see IRIS, #93 5-Methoxy-3-ethoxy-4-methylthiophenethylamine see 3-TE, # 150 3-Methoxy-4-ethoxyphenethylamine see MEPEA 3-Methoxy-4,5-ethylenedioxyamphetamine see MEDA, #120 N-Methoxyethyl-MDA see MDMEOET, #112 N-(2-Methoxyethyl)-3,4-methylenedioxyamphetamine see MDMEOET, #112 3-Methoxy-4-hydroxyamphetamine see under MEPEA, #123 N-Methoxy-MDA see MDMEO, #111 B-Methoxymesca1ine see BOM, #17 2-Methoxy-N-methylamphetamine see under METHYL-DMA, #126 3-Methoxy-4-methylamphetamine see under MEPEA, #123 3-Methoxy-N-methylamphetamine see under METHYL-MA, #130 4-Methoxy-N-methy1amphetamine see METHYL-MA, #130 2-Methoxy-3,4-methy1enedioxyamphetamine see MMDA-3a, #134 2-Methoxy-4,5-methylenedioxyamphetamine see MMDA-2, #133 3-Methoxy-4,5-methylenedioxyamphetamine see MMDA, #132 4-Methoxy-2,3-methylenedioxyamphetamine see MMDA-3b, #135 5-Methoxy-2,3-methylenedioxyamphetamine see underTMA-4, #160 6-Methoxy-2,3-methylenedioxyamphetamine see under MMDA-3b, #135 N-Methoxy-3,4-methylenedioxyamphetamine see MDMEO, #Ill 2-Methoxy-3,4-methylenedioxyphenethylamine see under MMDA-3a, #134 2-Methoxy-4,5-methylenedioxyphenethylamine see under MMDA-2, #133 3-Methoxy-4,5-methylenedioxyphenethylamine see LOPHOPHINE, #95 5-Methoxy-2,3-methylenedioxyphenethylamine see under TMA-4, #160 B-Methoxy-3,4-methylenedioxyphenethylamine see BOH, #15 1-(2-Methoxy-3,4-methylenedioxyphenyl)-2-aminobutane see under MMDA-

3a, #134 1-(2-Methoxy-4,5-methylenedioxyphenyl)-2-aminobutane see under MMDA-

2,#133 2-Methoxy-4,5-methylenethiooxyamphetamine see 4T-MMDA-2, #167 2-Methoxy-5,4-methylenethiooxyamphetamine see under 4T-MMDA-2, #167 3-Methoxy-5,4-methylenethiooxyamphetamine see under 2T-MMDA-3a, #166 2-Methoxy-N-methyl-4,5-methylenedioxyamphetamine see METHYL-


MMDA-2, #131 2-Methoxy-4-methyl-5-methylsulfinylamphetamine see TOMSO, #173 2-Methoxy-4-methyl-5-methylthioamphetamine see 5-TOM, #172 5-Methoxy-4-methyl-2-methylthioamphetamine see 2-TOM, #171 2-Methoxy-4-methyl-5-methylthiophenethylamine see under 5-TOM, #172 5-Methoxy-4-methyl-2-methylthiophenethylamine see under 2-TOM, #171 Methoxyphenamine see under METHYL-DMA, #126 3-Methoxyphenethylamine see under PEA, #142 4-Methoxyphenethylamine see under PEA, #142 4-Methoxy-3,5-bis-(trideuteromethoxy)phenethylamine see 4-D, #50 4-Methoxy-2,3-(trimethylene)amphetamine see under 2C-G-3, #28 3-Methoxy-4,5-(trimethylenedioxy)amphetamine see under MEDA, #120 2-Methylamino-1-(3,4-methylenedioxyphenyl)butane see METHYL-J, #128 3-Methylamino-1-(3,4-methylenedioxyphenyl)butane see under PEA, #142 2-Methylamino-1-(3,4-methylenedioxyphenyl)hexane see under METHYL-K,

#129 2-Methylamino-1-(3,4-methy1enedioxypheny1)pentane see METHYL-K,#129 1-Methy1amino-1-(3,4-methy1enedioxyphenyl)propane see under MDA, #100 2-Methylamphetamine see under 2,5-DMA, #54 3-Methylamphetamine see under 2,5-DMA, #54 4-Methylamphetamine see under 2,5-DMA, #54 N-Methylamphetamine see under MDBU, #102 N-Methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine see METHYL-J, #128 N-Methyl-1-(1 ,3-benzodioxol-5-yl)-2-hexanamine see under METHYL-K,

#129 N-Methyl-1-( l ,3-benzodioxol-5-yl)-2-pentanamine see METHYL-K, #129 Methyl chavicol see under TMA, #157 METHYL-2C-T-7 see under 2C-T-7, #43 METHYL-DMA #126 page 774 METHYL-DMMDA see under METHYL-MMDA-2, #131 J3-Methyl-DMMDA see under DMMDA, #58 METHYL-DOB #127 page 776 METHYL-DOl see under IDNNA, #90 METHYL-DOM see BEATRICE, #11 3,4-Methylenedioxy-N-acetylamphetamine see under MDE, #102 3,4-Methylenedioxy-N-allylamphetamine see MDAL, #101 2,3-Methylenedioxyamphetamine see under MDA, #100 3,4-Methylenedioxyamphetamine see MDA, #100 3,4-Methylenedioxy-N-(n)-amylamphetamine see under MDBZ, #103 3,4-Methy1enedioxy-N-benzylamphetamine see MDBZ, #103 N-(3,4-Methylenedioxybenzyl)-N' -methylpiperazine see under PEA, #142 N-(3,4-Methylenedioxybenzyl)piperazine see under PEA, #142 4,5-Methylenedioxy-2-bromoamphetamine see 2-BR-4,5-MDA, #19

949


3,4-Methylenedioxy-N-(t)-butylaminoamphetamine see under MDBZ, #103 3,4-Methylenedioxy-N-(i)-butylamphetamine see under MDBZ, #103 3,4-Methylenedioxy-N-(n)-butylamphetamine see MDBU, #102 3,4-Methylenedioxy-N-(t)-butylamphetamine see under MDBZ, #103 3,4-Methylenedioxy-N-cyanomethylamphetamine see under MDBZ, #103 3,4-Methylenedioxy-N-(cyclopropylmethyl)amphetamine see MDCPM, #104 3,4-Methylenedioxy-N,N-diethylamphetamine see under MDBZ, #103 3,4-Methylenedioxy-2,N-dimethylamphetamine see under MADAM-6, #98 3,4-Methylenedioxy-N,N-dimethylamphetamine see MDDM, #105 4,5-Methylenedioxy-2,N-dimethylamphetamine see MADAM-6, #98 3,4-Methylenedioxy-N-ethylamphetamine see MDE, #106 4,5-Methylenedioxy-2-fluoro-N-methylamphetamine see under FLEA, #81 3,4-Methylenedioxy-N-(n)-heptylamphetamine see under MDBZ, #103 3,4-Methylenedioxy-N-(n)-hexylamphetamine see under MDBZ, #103 3,4-Methylenedioxy-N-hydroxyamphetamine see MDOH, #114 3,4-Methylenedioxy-N-(2-hydroxyethyl)amphetamine see DMHOET, #107 3,4-Methylenedioxy-N-hydroxy-N-methylamphetamine see FLEA, #81 3,4-Methy1enedioxy-B-hydroxyphenethylamine see under DMA, #57 3,4-Methylenedioxymephentermine see MDMP, #113 3,4-Methylenedioxymethamphetamine see MDMA, #109 3,4-Methylenedioxy-5-methoxyamphetamine see MMDA, #132 3,4-Methylenedioxy-N-methoxyamphetamine see MDMEO, #111 3,4-Methylenedioxy-N-(2-methoxyethyl)amphetamine see MDMEOET, #112 1-(3,4-Methylenedioxyphenyi)-N-methyl-2-aminobutane see METHYL-J,

#128 3,4-Methylenedioxy-N-methylamphetamine see MDMA, #109 3,4-Methylenedioxy-N-methylphenethylamine see under MDPEA, #115 3,4-Methylenedioxy-2-methylthioamphetamine see 2T-MMDA-3a, #166 3,4-Methylenedioxy-N-(n)-octylamphetamine see under MDBZ, #103 3,4-Methylenedioxyphenethylamine see MDPEA, #115 3,4-Methylenedioxyphentermine see MDPH, #116 1-(3,4-Methylenedioxyphenyl)-2-aminobutane see J, #94 1-(3,4-Methylenedioxyphenyl)-3-aminobutane see under PEA, #142 1-(3,4-Methy1enedioxyphenyl)-2-aminohexane see under METHYL-K, #129 1-(3,4-Methylenedioxyphenyl)-2-aminopentane see under METHYL-K, #129 N-(3,4-Methylenedioxyphenyi)-N' -(t)-butylhydrazine see under MDBZ, #103 2-(3,4-Methylenedioxyphenyl)-1, 1-dimethylethylamine see MDPH, #116 2-(3,4-Methylenedioxyphenyl)-2-ethanolamine see under DMA, #57 3-(3,4-Methylenedioxyphenyl)propylamine see under MDA, #100 2-(3,4-Methylenedioxyphenyi)-1,1,N-trimethylethylamine see MDMP, #113 3,4-Methylenedioxy-N-propargylamphetamine see MDPL, #117 3,4-Methylenedioxy-N-(i)-propylamphetamine see MDIP, #108 3,4-Methylenedioxy-N-(n)-propylamphetamine see MDPR, #118


3,4-Me thy lenediox y-N-(2,2,2-trifluoroethy !)amphetamine see under MD E, #106

Methyleugenol see under 3,4-DMA, #55 METHYL-H see under MDPEA, #115 METHYL-I see MDMA, #109 Methylisoeugenol see under 3,4-DMA, #55 METHYL-J #128 page 778 METHYL-K #129 page 781 METHYL-L see under METHYL-K, #129 METHYL-MA #130 page 783 METHYL-MDA see MDMA, #109 METHYL-MDPEA see under MDPEA, #115 METHYL-MESCALINE see under M, #96 N-Methyi-N' -(3,4-methylenedioxybenzyl)piperazine see under PEA, #142 N-Methyl-1-(3,4-methylenedioxyphenyl)-2-aminobutane see METHYL-J,

#128 N-Methyl-1-(3,4-methylenedioxyphenyl)-2-aminohexane see under METHYL

K, #129 N-Methyl-1-(3,4-methylenedioxyphenyl)-2-aminopentane see METHYL-K,

#129 a-Methylmescaline see TMA, #157 4-Methyl-2,5-bis-(methylthio)amphetamine see BIS-TOM, #12 4-Methyl-2,5-bis-(methylthio)phenethylamine see under BIS-TOM, #12 METHYL-MMDA-2 #131 page 785 METHYL-TMA see underMETHYL-DMA, #126 METHYL-TMA-2 see underMETHYL-DMA, #126 METHYL-TMA-6 see under METHYL-DAM, #126 4-Methyl-2,3,6-trimethoxyamphetamine see under 'P-DOM, #69 4-Methyl-2,5,8-trimethoxyphenethylamine see BOD, #14 N-Methyl-2,4,5-trimethoxyamphetamine see under METHYL-DMA, #126 N-Methyl-2,4,6-trimethoxyamphetamine see under METHYL-DMA, #126 N-Methyl-3,4,5-trimethoxyamphetamine see under METHYL-DMA, #126 N-Methyl-3,4,5-trimethoxyphenethylamine see under M, #96 MIP see under MP, #137 MIPM see under MPM, #138 MMA see under MEPEA, #123 4-MMA see METHYL-MA, #130 MMDA #132 page 787 MMDA-2 #133 page 792 MMDA-3a #134 page 795 MMDA-3b #135 page 798 MMDA-4 see underTMA-4, #160 MMDA-5 see under MMDA-3b, #135

951


MME #136 page 800 2-MNNA see under METHYL-MA, #130 4-MNNA see under METHYL-MA, #130 MP #137 page 803 MPEA see under PEA, #142 3-MPEA see under PEA, #142 MPM #138 page 806 MTDA see under MEDA, #120 Mugwort see under TMA, #157 MUNI-METRO series see under METHYL-J, #128 Myristicin see under MMDA, #132 Myristin see under TMA, #157 Myrrh see underTMA, #157 Myrtle see under TMA, #157 NIMITZ see 2C-T -17, #48 a-Nonylmescaline see under AEM, #1 3,4-Norbornyl-2,5-dimethoxyamphetamine see G-5, #84 3,4-Norbornyl-2,5-dimethoxyphenethylamine see 2C-G-5, #30 Nothosmyrnol see under TMA, #157 Nutmeg see under TMA, # 157 N-Octyi-MDA see under MDBZ, #103 a-Octylmescaline see under AEM, #1 ORTHO-DOB see under MET A-DOB, #24 ORTHO-DOT #139 page 809 ORTHO-MDA see under MDA, #100 Orthoxine see under METHYL-DMA, #126 Osmorrhizole see underTMA, #157 P #140 page 811 PARA-DOT see ALEPH, #3 Parsley see underTMA, #157 PE #141 page 813 PEA #142 page 815 Pentescaline see under B, #10 Pepper see under TMA, #157 Peyote see under M, #96 Phenescaline see PE, # 141 Phenethylamine see PEA, #142 Phenylacetic acid see under PEA, #142 Phenylmescaline see under PE, #141 N-Phenylpiperizines see under PEA, #142 Phenyl-(cyclo)-propylamines see under PEA, #142 Phenyl-(iso)-propylamines see under PEA, #142 Phenyl-(normal)-propylamines see under PEA, #142


Piggy-back see under MOE, #106; MDIP, #108 and MDPR, #118 Pimento see under TMA, #157 Pink Spot see under DMPEA, #60 PM see under PE, #141 PMA see 4-MA, #97 PMMA see METHYL-MA, #130 Primer see MDPR, #118 N-Propargyl-MDA see MDPL, #117 N-Propyl-MDA see MDPR, #118 a-Propy1mescaline see under AEM, #I PROPYNYL #143 page 819 Proscaline seeP, #140 Pseudo-analogues, or '¥-analogues, see under ARIADNE, #8 Pseunut cocktail see under TMA, #157 Rat-root see under TMA, #157 Reciprocal Mescaline see IM, #91 Rue see underTMA, #157 Safrole see under MDA, #100 S see under B, #10 Sage see underTMA, #157 Sassafras see under TMA, #157 SB #144 page 820 Scrudge see under 3-TSB, #176 Sekishone see under TMA, #157 Septescaline see under B, #10 SESQUI see 2C-T-15, #47 SKF-5 see MDA, #100 Spices see underTMA, #157 STP see DOM, #68 Sweet flag see underTMA, #157 Symbescaline see SB, #144 T A #145 page 822 Tarragon see under TMA, #157 3-TASB #146 page 826 4-TASB #147 page 829 5-TASB #148 page 832 TB #149 page 834 TE see 4-TE, #151 3-TE #150 page 837 4-TE #151 page 840 Ten Classic Ladies see under ARIADNE, #8 Ten Essential Amphetamines see under TMA, #157 2,3,4,5-Tetramethoxyamphetamine see TA, #145

953


3,4,5,6-Tetramethoxyphenethylamine see BOM, #17 2,5,N,N-Tetramethylamphetamine see under 2,5-DMA, #54 3-Thioasymbescaline see 3-TASB, #146 4-Thioasymbescaline see 4-TASB, #147 5-Thioasymbescaline see 5-TASB, #148 Thiobuscaline see TB, #149 3-Thioescaline see #ISO 4-Thioescaline see 4-TE, #151 2-Thioisomescaline see 2-TIM, #152 3-Thioisomescaline see 3-TIM, #153 4-Thioisomescaline see 4-TIM, # 154 3-Thiomescaline see 3-TM, #155 4-Thiomescaline see 4-TM, #156 3-Thiometaescaline see 3-TME, #163 4-Thiometaescaline see 4-TME, #164 5-Thiometaescaline see 5-TME, # 165 Thioproscaline see TP, #174 3-Thiosymbescaline see 3-TSB, # 176 4-Thiosymbescaline see 4-TSB, #177 3-Thiotrescaline see 3-T-TRIS, #178 4-Thiotrescaline see 4-T-TRIS, #179 3-Thiotrisescaline see 3-T-TRIS, #178 4-Thiotrisescaline see 4-T-TRIS, #179 2-TIM #1S2 page 843 3-TIM #1S3 page 846 4-TIM #1S4 page 848 TM see 4-TM, #156 3-TM #ISS page 849 4-TM #1S6 page 852 TMA #157 page 857 TMA-2 #ISS page 864 '1'-TMA-2 see TMA-6, #162 TMA-3 #1S9 page 868 TMA-4 #160 page 869 TMA-S #161 page 873 TMA-6 #162 page 876 3-TME #163 page 880 4-TME #164 page 882 S-TME #16S page 884 2T-MMDA-3a #166 page 886 4T-MMDA-2 #167 page 888 5T-MMDA see under 2T-MMDA-3a, #166 5T-MMDA-2 see under4T-MMDA-2, #167


TMPAA see under M, #96 TMPEA #168 page 891 2,3,4-TMPEA see IM, #91 2,3,5-TMPEA see under TMA-4, #160 2,3,6-TMPEA see under TMA-5, #161 2,4,5-TMPEA see TMPEA, #168 2,4,6-TMPEA see underTMA-6, #162 3,4,5-TMPEA see M, #96 TMT see under DMCPA, #56 2-TOET #169 page 893 5-TOET #170 page 896 2-TOM #171 page 900 5-TOM #172 page 904 TOMSO #173 page 907 TP #174 page 909 Tree tea see underTMA, #157 Tresca1ine see TRIS, #175 Trichocerine see under M, #96 3,4,5-Tridesoxymesca1ine see under DESOXY, #52 3,5-bis-Trideuteromethoxy-4-methoxyphenethylamine see under B-D, #51 2,4,5-Triethoxyamphetamine see EEE, #73 3,4,5-Triethoxyphenethylamine see TRIS, #175 N-(3-Trifluoromethylphenyl)piperizine see under PEA, #142 3,4,5-Trimethoxy-N-acetylphenethylamine see under M, #93 2,3,4-Trimethoxyamphetamine see TMA-3, #159 2,3,5-Trimethoxyamphetamine see TMA-4, #160 2,3,6-Trimethoxyamphetamine see TMA-5, #161 2,4,5-Trimethoxyamphetamine see TMA-2, #158 2.4.6-Trimethoxyamphetamine see TMA-6, #162 3,4,5-Trimethoxyamphetamine see TMA, #157 3,4,5-Trimethoxy-2,6-dideuterophenethylamine see under B-D, #51 3,4,5-Trimethoxy-a,a-dideuterophenethylamine see under B-D, #51 3,4,5-Trimethoxy-B,B-dideuterophenethylamine see B-D, #51 2,3,4-Trimethoxyphenethylamine see IM, #91 2,3,5-Trimethoxyphenethylamine see under TMA-4, #160 2,3,6-Trimethoxyphenethylamine see under TMA-5, #161 2,4,5-Trimethoxyphenethylamine see TMPEA, #168 2,4,6-Trimethoxyphenethylamine see underTMA-6, #162 3,4,5-Trimethoxyphenethylamine see M, #96 2-(3,4,5-Trimethoxyphenoxy)-N,N-dimethylethylamine see under M, #96 3,4,5-Trimethoxyphenylacetic acid see under M, #96 1-(2,4,6-Trimethoxyphenyl)-2-aminobutane see under ARIADNE, #8 1-(3,4,5-Trimethoxyphenyl)-2-aminobutane see AEM, #I

955

)56 PIHKAL- A Chemical Love Story

1-(3,4,5-Trimethoxyphenyl)-2-aminodecane see under AEM, #1 1-(3,4,5-Trimethoxyphenyl)-2-aminoheptane see under AEM, #1 1-(3,4,5-Trimethoxyphenyl)-2-aminohexane see under AEM, #1 1-(3,4,5-Trimethoxyphenyl)-2-aminononane see under AEM, #1 1-(3,4,5-Trimethoxyphenyl)-2-aminooctane see under AEM, #l 1-(3,4,5-Trimethoxyphenyl)-2-aminopentane see under AEM, #I 1-(3,4,5-Trimethoxyphenyl)-2-aminoundecane see under AEM, #1 2-(3,4,5-Trimethoxyphenyl)cyclopropylamine see under DMCPA, #56 3,4,5-Trimethoxytranylcypromine see under DMCPA, #56 a,a,N-Trimethyl-3,4-methylenedioxyphenethylamine see #113, MDMP 3,4,5-Trimethy1phenethylamine see under DESOXY, #52 TRIS #175 page 912 Trisescaline see TRIS, #175 3-TSB #176 page 913 4-TSB #177 page 916 2-T-TMA-3 see under 2-TIM, #152 3-T-TMA see under 3-TM, #155 3-T-TMA-3 see under 2-TIM, #152 4-T-TMA-3 see under 2-TIM, #152 3-T-TRIS #178 page 918 4-T-TRIS #179 page 921 Tweetio see under 2C-D, #23 X see MDMA, #109 Xixin see under TMA, #157 XTC see MDMA, #109 Xylopropamine see under 2,5-DMA, #54 Yellow Apiol see underTMA, #157 Z-7 see '1'-DOM, #69 Z-7.1 see under '1'-DOM, #69 Z-7.2 see under '1'-DOM, #69

Glossary

APPENDIX B: GLOSSARY

This is a dictionary of terms that have commonly been used in and about the area of psychedelic drug experimentation. Many of these are common words, but in immediate application to this particular area of inquiry, they can carry different meanings than usual. These are our definitions of terms we have used in this book.

Ambrose Bierce composed a Devil' s Dictionary over the course of 25 years, at the tum of the last century. His definition of a dictionary is most apt:

DICTIONARY, n. A malevolent literary device for cramping the growth of a language and making it hard and inelastic. This dictionary, however, is a most useful work.

We hope that our little dictionary, too, will prove useful, and that our efforts to give simple descriptions of what can be complex concepts will serve to clarify what we have written.

ACUTE, adj. A single exposure to a drug.

AFTERGLOW, n. A state of total peace and contentedness that can follow on the heels of a psychedelic experience. There is a well-known term, POT, or postorgasmic tranquility, that implies a drifting, a de-stressed period of inattention and reflection, calmness and placidity; this can also be a major part of the drop-off and recovery period following the use of a psychedelic. It is the smile on the face of the Buddha.

ALERT, n. The first clue that a drug will show activity. Each researcher, with

957


experience, comes to recognize his own personal alert. It may be a tinge of lightheadedness, a chill, or a brief raising of the hair on his neck, and simply serves as a reminder that he took something half an hour (or a couple of hours) ago. Sometimes an alert can follow very soon after the taking of the drug, without any further effects becoming apparent until some time later. Each person's alert tends to be experienced consistently, regardless of the nature of the drug being researched.

ANOREXIC, adj. (Or anorectic.) Related to anorexia, meaning loss of appetite. Some of the psychedelic drugs, especially those with a considerable stimulant component, can quite effectively wipe out all desire to eat. Unfortunately (for most of us), there are others, especially those with a strong sensory component, which achieve quite the opposite effect.

ASC Altered state of consciousness.

ASSAYING, see RUNNING UP.

AWARENESS, see ALERT.

BASELINE, n. The normal psychological and physical state of a person prior to the start of an experiment which, once regained, marks the end of that experiment.

BODY LOAD, n. Any sense of unease in the physical body, such as nausea, aching, heaviness, or the feeling of being "wired," or over-stimulated. For some people, diarrhea is considered a form of body load, while for others it is an expected part of most psychedelic experiments, and is regarded as a welcome cleaning out of the system. One elderly and very experienced psychologist considered nausea and vomiting to be a positive event; he welcomed it as a sign that the experimental drug was active, and for him, it meant the beginning of his experience. His attitude, however, was very much the exception and we haven't heard of anyone else doing this research who regards nausea quite that fondly.

CENTRAL NERVOUS SYSTEM The part of the nervous system that involves the brain, the brain stem, and the spinal column. It is to this system that all senses connect (the afferent pathways) and it is from this system that all motor commands emanate (the efferent pathways).

CHRONIC, adj. Repeated exposure to a drug.

CLEAN, adj. To be in that state of body which results from having declined the

Glossary

use of any psychoactive drug for a period of time. For some people, that might well be months, or even years, but for those who are continuously experimenting with new materials, and who are primarily worried about the masking of effects due to tolerance or refractoriness, it is more likely to mean a period of four or five days.

CNS, see CENTRAL NERVOUS SYSTEM

CONSCIOUS, adj. Used most commonly in phrases such as "the conscious mind," or "being conscious of." It is the term applied to that part of the human psyche which is aware of its surroundings, and is capable of being aware of its own existence and observing its own functioning. It has been speculated that the conscious mind also serves as a filter, to prevent the activities of the unconscious psyche from flooding the field of waking awareness. In sleep, the conscious, self-aware mind is usually, for the most part, at rest, and the unconscious part of the psyche becomes activated.

CONTACT HIGH, n. A common occurrence in a group experiment with a psychedelic drug is that a drug-free observer becomes aware that he is experiencing some effects of the material being used by the others. The altered state has become contagious. Animals in the household are especially prone to this kind of unintentional participation, usually appearing to enjoy it immensely. There is no known scientific explanation for this phenomenon.

CROSS-TOLERANCE, n. The decrease or loss of response to a drug due to recent (or prolonged) exposure to a different drug that displays some pharmacological similarities. see also TOLERANCE.

DARTING, n. A sudden and unexpected neurological firing that produces a momentary contraction of the musculature. It may occasionally occur when falling asleep while still at a plus two level of effect. It also occurs under normal conditions involving no drug at all.

DECLINE, n. or v. The period that follows the plateau, during which there is a loss of the drug's effects and an eventual recovery of one's baseline state. From person to person, this is the most variable of the time periods in a drug experiment. It has also been called recovering, tapering off, or dropping off.

DEVELOPING, v. The period of change from the onset of effects to the achievement of the plateau. It is also called the transition. The temporal sequence terminology is: taking the drug, alerting, developing, plateauing, declining, and reestablishment of (or being at) baseline.

959


DROPPING, see TAKING, also see DECLINING.

DRUG-DRUG INTERACTIONS, see PIGGYBACKING, PRIMER and SYNERGISM.

DRUG-FREE, see CLEAN.

ENERGY TREMOR, n. A sensation of heightened responsiveness and sensitivity which may be actually experienced as a fine body tremor with visible shaking, or simply felt as excitement.

EUPHORIA, n. "Eu-" is a prefix that means "normal." Euphoria is from the Greek, euphoria, literally a "bearing well," from eu, meaning well, and pherein, to bear. The original meaning is a normal state of feeling, as opposed to dysphoria, which means an abnormal state of feeling. In the field of medicine, to give another example, the term euthyroid means a normal, healthy state of the thyroid gland, as opposed to dysthyroid, which indicates an abnormal condition of that gland (usually either hyper- or hypothyroid).

The fact that the word euphoria has come to mean a state of feeling better -or much, much better- than usual, should give us pause. The implication is that our customary state is one of dysphoria, and that what has come to be considered the proper and normal way to feel in our everyday life is, in actuality, a state of depression.

This term must not be confused with U-4-E-uh, a name given to the drug 4-methylaminorex.

EXPERIENCED TRAVELER A person who can remember to feed the cats while under the influence of a psychedelic drug.

FANTASY, n. The eyes-closed construction of an interior world which can become believable to the point where the subject confuses it with objective reality, until and unless he opens his eyes. At high dosage levels of a psychedelic drug, some subjects may forget to open their eyes occasionally, and may find themselves totally captured by and immersed in the fantasy landscape and interactions, as happens in normal dreaming.

FLASH-BACK, n. The rare but not unknown recapitulation of a psychedelic experience at a time when there is no drug present. A reasonable explanation is that there had been, during a past psychedelic experience, some unusual stimulus which had become associated with it, and that, at some subsequent time, a re-experiencing of that unusual stimulus could reprecipitate the psychedelic state. The main reason that the average man views this phenomenon as something negative, is that the average man has been taught to view the

Glossary

psychedelic state as something negative.

FUGUE STATE, n. As used in this book, a transient disorientation that separates the cognitive part of oneself from the sensory part. There is a loss of understanding of the symbolic interpretations of words and things, with only the literal and tangible meanings left for personal use. This is our definition of the word, not that of the medical profession.

GRAM, n. The basic unit of weight on the metric scale, a system used for weights and distances and volumes in all countries other thari the United States and, I believe, Brunei. The common subdivisions of the gram is into a thousand parts called milligrams, or a million parts called micrograms. Imagine that you are sitting down to eat a couple of eggs over easy. You take the salt shaker, and give three or four light shakes of salt over the surface of your breakfast. That is about a fourth of a gram of salt, or 250 milligrams. This is equivalent to the weight of a typical dose of mescaline. And in that 250 milligrams of salt there are maybe 5,000 grains, or individual crystals. Each grain weighs maybe 50 micrograms, which is equivalent to the weight of a low-level dose of LSD.

HALLUCINATION, n. An extremely rare phenomenon, in which a completely convincing reality surrounds a person, with his eyes open, a reality that he alone can experience and interact with. The inducement of hallucinations is a property that is commonly attributed to psychedelic drugs, but in reality is virtually non- existent in the use of such materials. In almost all psychedelic experiences undergone by normal, healthy people, there is an awareness of real surroundings. Visual distortions are common, but they are not confused with objective reality by the subject; they are known to be visual distortions and appreciated as such. The delusional anesthetic drugs, such as scopolamine and ketamine, on the other hand, can and do produce true hallucinations.

HALLUCINOGENS, n. A misleading and inaccurate synonym for psychedelic drugs.

HAND IN THE AIR In any psychedelic experience involving two or more people, there can be a shifting of one's reality reference point and a concomitant potential for mental game-playing. In our research group, a phrase that is unquestioned as being a prelude to a not-game comment is, "Hand in the air." It means that whatever follows is a serious, non-stoned, non-mind-fuck statement. "I smell smoke" could be the entry to an editorial on cigarette smoking or a remark on some aspect of politics. But, "Hand in the air; I smell smoke," is intended to cut right through any fantasy or game and must be taken seriously. This particular agreement, or rule, is never violated.

961

~62 PIHKAL- A Chemical Love Story

HARDHEAD, n. There is an occasional person who requires 200 milligrams of MDMA, or 300 micrograms of LSD, just to get some beginnings of effect. Whatever the drug might be, he will need twice or five times the dosage required by most other people. This may be due to psychological barriers that must be overcome, or it may be due to the fact that he was born with a nervous system and physical chemistry which is unusually insensitive to the effects of drugs. The term hardhead implies a thick, tough skull, of course, and is often used by such subjects to describe themselves, always with a certain amount of pride.

HITCHHIKING, v. Sometimes an innocent, drug-free person will find himself strangely disturbed or uncomfortable in the presence of an experimental subject who is, unknown to him, experiencing the effects of a psychedelic drug; for instance in the checkout line at the supermarket. This unconscious awareness (or contact high) can produce a feeling of irritation, or even overt hostility, in the inadvertent hitchhiker, and his or her distress is all the worse for having no apparent or understandable cause. The responsible psychedelic researcher does not go out in public when under the influence, or if he must do so, he takes care not to risk such intrusion on the unconscious psyches of strangers.

IDIOT, n. A person of either sex who drives a car, motorcycle, or even a bicycle, for that matter, on a public road while under the influence of a psychedelic drug. Most researchers in this area have done it at least once, sometimes in an emergency, but only in a life-and-death situation is it excusable.

IMAGERY, n. Figures, lines and shapes of all kinds, including fine filigree and intricate patterns, superimposed on the dark visual field behind closed eyes. Music can serve as a template for the construction of these images. There is no confusion of realities as can happen with fantasy, but instead, a continuing complexity and richness of design. Such images disappear upon the opening of the eyes. To be precise, they should be referred to as eyes-closed imagery. Patterns and movements seen with the eyes open are called visual changes or visual images.

INFLATION, n. An exhilarating sense of self-importance, self-validation and fearless power. It is essential that any researcher seeking insight into the workings of the human mind experience this radiant state at least once, in order to learn its nature and, by contrast, the nature of a normal, well-balanced state of integration and self-validation. It is also important to his/her understanding of psychological inflation in emotionally disturbed people and in the rulers of certain nations.

Glossary

INGESTION, see TAKING

INTOXICATION, n. This word has the same general meaning in the psychedelic area as it has among drinkers of alcohol and people in love.

KETAMINE STATE Used to indicate a state of consciousness alteration which involves a large degree of dissociation from the body. Users of ketamine can become adept at remaining integrated with their physical world by carefully monitoring their dosage levels and keeping them low, but most ketamine use tends to result in separation from the body and its concerns. We are strongly prejudiced against psychedelic drugs which cause such mind-body separation, as we are against any drug which causes separation from feelings and emotions. However, we acknowledge that the ketamine state can be highly instructive for researchers trying to understand the functions of the human mind.

LAUNCHING, see TAKING

MACHO, adj. This describes a person of either sex who pushes his limits too much in experimentation with psychedelics. He always strives to take a higher and yet higher dosage, to prove that he can weather the storm. Such a person should be encouraged to do some intensive insight work into his compulsion, which is essentially self-destructive.

MINUS, n. On the quantitative potency scale(-,±,+,++,+++), there were no effects observed.

MYDRIASIS, n. Enlargement of the pupil of the eye.

NAIVE, adj. An adjective used to describe a person who has had no personal experience with any psychedelic drug. More properly, the term used should be "drug-naive."

NIBBLING, v. This is a jargon term for running up, in small increments, the human evaluations of a new compound. (See under "running up")

NOISE, n. A term used in describing the inner busyness of the mind, the excessive or annoying mental input, produced by certain psychedelic drugs, or characteristic of the initial - transition - stages of some drug experiments. It can also result simply from too high a dosage level.

OFF BASELINE, see ALERT

PARESTHESIA, n. A peripheral response to a drug which can be felt as tingling,

963


pins-and-needles, or hair standing on end; it might take the form of a chill (even if the air is warm), or a feeling that one's skin is crawling.

PIGGYBACKING, v. A study of the interaction of two different drugs, the second being administered in place of a supplement to the first. Any deviation from the effects that would have followed a supplement of the original drug will give additional information as to the nature of the second drug.

PLATEAU, n. or v. The period of time spent at the level of maximum effect of whatever drug has been ingested, at the particular dosage given. It is preceded by the transition and development, and is followed by the decline. As a verb, "to plateau" means to reach that level of drug effect.

PLUS/MINUS, n. (±) The level of effectiveness of a drug that indicates a threshold action. If a higher dosage produces a greater response, then the plus/minus (±) was valid. If a higher dosage produces nothing, then this was a false positive.

PLUS ONE, n. ( +) The drug is quite certainly active. The chronology can be determined with some accuracy, but the nature of the drug's effects are not yet apparent.

PLUS TWO, n. (++) Both the chronology and the nature of the action of a drug are unmistakably apparent. But you still have some choice as to whether you will accept the adventure, or rather just continue with your ordinary day's plans (if you are an experienced researcher, that is). The effects can be allowed a predominent role, or they may be repressible and made secondary to other chosen activities.

PLUS THREE, n. (+++) Not only are the chronology and the nature of a drug's action quite clear, but ignoring its action is no longer an option. The subject is totally engaged in the experience, for better or worse.

PLUS FOUR, n. ( ++++) A rare and precious transcendental state, which has been called a "peak experience," a "religious experience," "divine transformation," a "state of Samadhi" and many other names in other cultures. It is not connected to the +1, +2 and +3 of the measuring of a drug's intensity. It is a state of bliss, a participation mystique, a connectedness with both the interior and exterior universes, which has come about after the ingestion of a psychedelic drug, but which is not necessarily repeatable with a subsequent ingestion of that same drug. If a drug (or technique or process) were ever to be discovered which would consistently produce a plus four experience in all human beings, it is conceivable that it would signal the ultimate evolution,

Glossary

and perhaps the end of, the human experiment.

POTENTIATION, n. The influence of an inactive drug on the effects realized from an active drug.

PRIMER, n. A word used in the study of the interaction of two different drugs, one of them without activity. The inactive, "primer," drug is administered and, while it is still in the system, the second, "primed," drug is given. Any activity observed which is different from that expected from the primed drug alone will be a measure of potentiation. The effect may be one of enhanced action; it may be that of decreased action; it may be a change in either quality or duration of activity.

PRIMING, see PRIMER

PRODRUG, n. A chemical that is intrinsically without activity at a receptor site, but which is converted (activated) by the metabolic processes of the body.

PSYCHE, n. A term used to encompass the non-physical human mind, conscious and unconscious, including feelings and emotions. The word, psyche, has come into modem use as a substitute for the more ancient, but scientifically unapproachable, concept of soul.

PSYCHEDELIC, n. or adj. As an adjective, meaning pertaining to a change in the normal state of consciousness, usually with some accompanying changes in the acuity of the senses. Also, "mind-manifesting." As a noun, a drug that can allow such changes to occur. The word was coined by Doctor Humphrey Osmond in the 1950's.

PSYCHOTOMIMETIC, n. or adj. A name given to the psychedelic drugs to emphasize some supposed similarities between certain of their effects and the psychotic state. The word unites the prefix psychoto- (referring to psychosis) with the suffix -mimetic (meaning imitation). It was one of the earliest terms used for these drugs, and one which implied medical approval of the use of such drugs, at least as research tools.

RECOVERY, see DECLINE

REFRACTORY, adj. The state of showing a reduced response to the action of a drug. This may be due to tolerance resulting from recent exposure, the action of some inhibitor, or a condition of health or expectation that interferes with the expected action.

965


RUNNING UP, v. The process of searching for activity in a new drug by a strategy of taking incrementally larger and larger doses, at time intervals which are calculated to minimize the development of tolerance. A usual pattern is an increase of either 60% or 100% of the previous dosage, following a clean period of several days, until activity is detected. There are many popular terms for this titration process, such as nibbling, assaying, or tasting.

SAMADHI, n. A word in the terminology of the Yoga which represents a direct union with ultimate reality, allowing the dissolving of the ego and an achievement of a state of bliss. Used by western researchers, the word does not necessarily imply a dissolving of ego, but a transformation of it.

SCRUDGE, n. (Defined in Book II, entry #176)

STARTING, see TAKING

STONED, adj. This generally means being under the influence of a psychoactive drug. It is a widely used word, and we have employed it in our story as carelessly as most people do. However, in writing a report on the effects of an experimental drug, there is actually an important difference between being "stoned" and being "turned-on," and the researcher should make a distinction between them. A stoning effect is one in which there is awareness of a strongly altered state of consciousness; it may be pleasurable or unpleasant. It is characterized, usually, by a general inability and disinclination to deal with concepts or to employ insight. In other words, one finds it difficult to learn anything of value. On the other hand, being turned on is simply to be aware of a change in one's mind and/or body in the direction of an increased sense of physical and mental energy. Being turned on is usually thought of as positive, whereas there are many researchers who do not enjoy being stoned at all.

STRAIGHT, adj. The state of being at baseline, with no psychedelic drug present in the body,

SUBACUTE, adj. An occasional or short-term exposure to a drug.

SUPPLEMENT, n. or v. The administration of a second dose of an active drug, during the drop-off phase of the activity of an initial dosage. The usual consequence is a prolongation of effect, with a concomitant increase in signs of toxicity.

SYNERGISM, n. The interaction of two drugs, often administered at the same time, which produces a response that is not simply additive. The summed responses may be exaggerated (positive synergy), or attenuated (inhibition).

Glossary

SYNESTHESIA, n. An activation of two or more senses simultaneously; for instance, sound may be "seen" in the mind as being composed of color and shape, or a color may be "heard" as a musical note or harmony. There are innumerable examples of this melding together of the senses, and the experience is generally considered one of the most treasured effects of a psychedelic drug. There are many people who live in a world of synesthesia continuously, without benefit of drug, having been born with this ability. For the most part, they regard themselves as profoundly blessed.

TAKING, v. The actual ingestion of a drug. When there are several persons involved, any of several rituals can be followed; a toasting and clinking of glasses, the recital of an favorite prayer, or a touching of hands and brief silence. The taking of a drug has also been called "launching," "dropping," "taking off' or, simply, "starting."

TAPERING OFF, see DECLINE

TASTING, see RUNNING UP

THRESHOLD, n. A dosage of a drug that gives some detectable change from baseline. A minimum detectable effect of a drug.

TIME-DISTORTION A mis-perception or distortion concerning the subjective passage of time. With psychedelic drugs, there is almost always a sense that time is passing more slowly than usual. This may be recognized at the global level (you mean it's only been an hour since we took this stuff?), at the clockwatching level (I've been watching the second hand and I've found I can really slow it down), or at the afferent level (where, for instance, the radio pitch and the pulse rate might appear to have dropped considerably).

TITRATE, v. To determine the effective level of a drug by the sequential taking of graded doses, at separated intervals. see RUNNING UP.

TOLERANCE, n. The decrease or loss of response to a drug, due to recent or prolonged exposure to it.

TOMSO, n. or v. Used as a noun: a sulfur-containing drug, described in detail in Book II, entry # 173. Used as a verb: to instigate or promote an altered state of consciousness during exposure to an ineffective dosage of a psychedelic drug, by the absorption of a modest amount of alcohol.

TRANSITION, see DEVELOPING

967


TRAVELER, n. A person who explores the effects of psychedelic drugs.

TURNED-ON, see STONED

UNCONSCIOUS, n. or adj. As an adjective, this is a simple word, meaning not being conscious. As a noun, it is a most complex word, meaning that part of the psyche which contains the building blocks of each individual identity, not accessible for most people in the everyday waking state. The sources, shapes and origins of these blocks, these components, are - to varying degrees -available to us in sleep, in certain states of mental disturbance, in hypnotic trance, meditation, artistic inspiration, and with the use of certain drugs. Intentional and conscious access to unconscious material can be achieved with the aid of psychedelic drugs, which is one of the values- and risks- of such exploration.

VISUALS, n. Changes in the visual area that are usually among the effects of a psychedelic drug. There may be an enhancement of colors, an exaggeration of light-dark contrast, a sparkling of lights, or a change in the visible texture or quality of an object. Some of the changes may reflect the mydriasis (enlargement of pupils) that is often one of the effects of such a drug. The term "visual effects" is also used to describe the apparent movement of objects in one's surroundings which may be seen with the eyes open, usually at higher than plus-two dosage levels of a psychedelic drug. These are not hallucinations, since they are known by the subject to be apparent and not objectively real, which is not the case in an hallucinatory experience.

WIRED, adj. A condition of intense neurological alertness, which suggests that the response to a given stimulus might be exaggerated by an overly sensitive nervous system.

Acknowledgements

APPENDIX C: ACKNOWLEDGEMENTS

There are here acknowledged the many sources upon which we have called for the information presented in this book. Much of it is from the scientific literature, and these citations are listed here. But as much is from the unpublished findings of a large number of individuals who have generously shared their information with us. These contributions have come from many quarters, from the crime labs oflaw enforcement to the seminar rooms of academia. They have included facts and suggestions ranging from drug law, to pharmacological effects, to book-writing procedures. An observation here and a comment there, when combined together, have enriched this presentation beyond what we could have done alone. Our sincere thanks to all of you, not only to those who have allowed us to list them with an acknowledgement of "personal communication" but also to those who, for whatever reason, have chosen to remain unnamed. We appreciate your contributions and respect your privacy.

Aldous, F.A.B., Barrass, B.C., Brewster, K., Buxton, D.A., Green, D.M., Pinder, R.M., Rich, P., Skeels, M. and Tutt, K.J., J. Med. Chern. 17, 1100-1111 (1974).

Aldrich, M., personal communication. Allen, A., personal communication. Alles, G.A., J. Am. Chern. Soc., 54,271-274 (1932). Alles, G.A., Neuropharmacology, Transactions of the Fourth Conference, The

Josiah Macy Jr. Foundation, 1959, p 181-268. Alter, J., personal communication. Anderson III, G.M., personal communication. Anderson III, G.M., Castagnoli Jr., N. and Kollman, P.A., NIDA Research

Monograph #22, U.S.G.P.O, 1978, p 199-217.

969


Angrist, B.M., personal communication. Angrist, B.M., Rotrosen, J. and Gershon, S., Psychopharmacologia 36,203-207

(1974). Angrist, B.M., Schweitzer, J.W., Friedhoff, A.J. and Gershon, S., Nature 225,

651-652 ( 1970). Anon. Microgram 20, 96 ( 1987). Anon. Microgram 21, 1 ( 1988). Autun, F.T. and Kurkjian, R. Brit. J. Psychiat. 140,611-614 (1982). Badine.r, A., personal communication. Bailey, K., By, A.W., Legault, D. and Verner, D., J.A.O.A.C. 58,62-69 (1975). Bailey, K., Gagne, D.R. and Pike, R.K., J.A.O.A.C. 59, 1162-1169 (1976). Bakalar, J., personal communication. Barfknecht, C.F. and Nichols, D.E., J. Med. Chern. 14,370-372 (1971). Barfknecht, C.F., Caputo, J.F., Tobin, M.B., Dyer, D.C., Standridge, R.T.,

Howell, H.G., Goodwin, W.R., Partyka, R.A., Gylys, J.A. and Cavanagh, R.L., NIDA Research Monograph Series #22, 1978 p 16-26.

Battersby, A.R., Dobson, T.A., Foulkes, D.M. and Herbert, R.B., J. Chern. Soc. Perkins Trans. p 1730 ( 1972).

Beck, J., personal communication. Beck, J., Harlow, D., McDonnell, D., Morgan, P.A., Rosenbaum, M. and

Watson, L., Exploring Ecstasy: A description ofMDMA Users, NIDA Report, September 1989.

Beck, W.S., Modern Science and the Nature of Life, Harcourt Brace, New York 1957, p 302.

Benington, F., personal communication. Benington, F., Batelle Technical Review, 1960, p 2. Benington, F. and Morin, R.D., J. Med. Chern. 14, 375 (1971). Benington, F., Morin, R.D. and Clark Jr., L.C., J. Org. Chern. 19, 11 (1954). Benington, F., Morin, R.D. and Clark Jr., L.C., J. Am. Chern. Soc. 76, 5555-

5556 (1954). Benington, F., Morin, R.D. and Clark Jr., L.C., J. Org. Chern. 20, 102 (1955). Benington, F., Morin, R.D., Clark Jr., L.C. and Fox, R.P., J. Org. Chern. 23,

1979 (1958). Beringer, K., Der Meskalinrausch Seine Geschichte und Erscheinungsweise,

Verlag von Julius Springer, Berlin (1927). Braun, G., personal communication. Braun, G., Shulgin, A.T. and Sargent III, T., J. Labelled Compounds and

Radiopharm. 14, 767-773 ( 1978). Braun, U., personal communication. Braun, U. and Kalbhen, D.A., Deut. Med. Wochen. 42, 1614-1615 (1972). Braun, U., Shulgin, A.T., Braun, G., J. Pharm. Sci. 69, 192-195 (1980). Braun, U., Shulgin, A.T., Braun, G., Arzn. Forsch. 30, 825-830 (1980). Braun, U., Shulgin, A.T., Braun, G. and Sargent Ill, T., J. Med. Chern. 20, 1543-

Acknowledgements

1546 (1977). Brown, W.T., McGeer, P.L. and Moser, 1., Can. Psychiat. J. 13, 91-92 (1968). Bruckner, V., J. Prakt. Chern. 138,268-274 (1933). Buffum, J., personal communication. Bunnell, S., personal communication. By, A.W., Duhaime, R. and Lodge, B.A., For. Sci. lntemational49, 159-170

(1991). Callaway, E., personal communication. Callaway, J., personal communication. Campbell, H., Cline, W., Evans, M., Lloyd, J. and Peck, A.W., Europ. J. Clin.

Pharmacol. 6, 170-176 (1973). Carlino, J., personal communication. Carlino, L., personal communication. Carlsson, A., Corrodi, H. and Magnusson, T., Helv. Chim. Acta 46, 1231-1235

(1963). Cash, L., personal communication. Cass, H., personal communication. Cassels, B.K., personal communication. Cassels, B.K. and Gomez-Jeria, J.S., J. Psychoactive Drugs 17, 129-130 (1985). Castagnoli Jr., N., personal communication. Charalampous, K.D. and Tansey, L.W. J. Pharm. and Exptl. Therap. 155, 318-

329 (1967). Charalampous, K.D., Orengo, A., Walker, K.E. and Kinross-Wright, J., J.

Pharm. Exptl. Therap. 145, 242-246 (1964). Charalampous, K.D., Walker, K.E. and Kinross-Wright, J.,

Psychopharmacologia 9, 48 (1966). Cheng, A.C. and Castagnoli Jr., N., J. Med. Chern. 27,513-520 (1984). Cheng, H.C., Long, J.P., Nichols, D.E. and Barfknecht, C.F., J. Pharm. Exptl.

Therap.l88, 114-123 (1974). Cimbura, G., J. Can. Med. Assn. 110, 1263-1267 (1974). Clark Jr., L.C., Benington, F. and Morin, R.D., J. Med. Chern. 8, 353-355

(1965). Clark, C.C., J. Forensic Sci. 29, 1056-1071 (1984) Cohn, R., personal communication. Collins, C., personal communication. Cooper, P.D. and Walters, G.C., Nature 238, 96-98 (1972). Coutts, R.T and Malicky, J.L., Can. J. Chern. 51, 1402-1409 (1973). Cozzi, N., personal communication. Dal Cason, T.A., personal communication. Dal Cason, T.A., J. Forensic Sci. 34,928-961 (1989). Dal Cason, T.A. and Janesko, J.L., National Meeting of the American Academy

of the Forensic Sciences, San Diego, CA February, 1987. Davis, B.A. and Boulton, A.A., Eur. J. Mass Spec. Biochem. Med. Environ .

•

971


Res. 1, 149-153 (1980). Devgan, O.N. and Bokadia, M.M. Austral. J. Chern. 21, 3001-3003 (1968). de Zan, P., Microgram 4, 5-11 ( 1971 ). de Zorzi, C. and Cavalli, A. Zacchia, 10, 3-11 (1974). Dittrich, A. Psychopharmacologia 21, 229-237 (1971). Doblin, Rick, personal communication. Domelsmith, L.N., Eaton, T.A., Houk, K.N., Anderson III, G.M., Glennon,

R.A., Shulgin, A.T., Castagnoli Jr., N. and Kollman, P.A., J. Med. Chern. 24, 1414-1421 (1981).

Downing, J., personal communication. Duberman, J. personal communication. Dudlettes, S.D., personal communication. Ehrlich, B., personal communication. Ely, R., personal communication. Entel, J., Ruof, C.H. and Howard, H.C., J. Am. Chern. Soc. 73, 2365 (1951). Fairchild, M.D., Doctorate Thesis, Department of Pharmacology, University of

California at Los Angeles, 1963. Fentiman Jr., A.F. and Foltz, R.L., J. Labelled Compounds Pharmaceut. 12, 69-

78 (1976). Ferguson, M., personal communication. Fijusawa, T. and Deguchi, Y., J. Pharm. Soc. Japan 74, 975-977 (1954). Fischer, E., Biological Mechanisms of Schizophrenia and Schizophrenia-like

Psychoses, Mitsuda and Fukuda, Eds. Georg Thieine, Stuttgart, 1975 p 177. Freye, H., personal communication. Friedhoff, A.J. and Schweitzer, J.W., Dis. Nerv. System 29, 455-456 (1968). Friedhoff, A.J. and Van Winkle, E., Nature 194, 897 (1962). Fritscher, R., personal communication. Garfinkel, S., personal communication. Gerdes, J.M., personal communication. Gerdes, J.M., Mathis, C.A. amd Shulgin, A.T. Tetrahedron Lett. 29,6537-6540

(1988). Gill, S., personal communication. Glennon, R.A., Life Sciences 39, 825-830 (1986). Glennon, R.A., lsmaiel, A.E-K.M., Martin, B., Poff, D. and Sutton, M.,

Pharmacol. Biochem. Behav. 31,9-13 (1988). Glennon, R.A., Liebowitz, S.M. and Anderson III, G.M., J. Med. Chern. 23,

294-299 (1980). Glennon, R.A., Liebowitz, S.M. and Mack, E.C., J. Med. Chern. 21, 822-825

(1978). Glennon, R.A., Seggel, M.R., Soine, W.H., Herrick-Davis, K., Lyon, R.A. and

Titeler, M., J. Med. Chern. 31,5-7 (1988). Glennon, R.A., Young, R., Benington, F. and Morin, R.D., J. Med. Chern. 25,

1163-1168 (1982).

Acknowledgements

Gomez-Jeria, J.S., Cassels, B.K., Clavijo, R., Vargas, V., Quintana, R. and Saavedra-Aguilar, J.C., Microgram 19, 153-161 (1986).

Gomez-Jeria, J.S., Cassels, B.K. and Saavedra-Aguilar, J.C., Eur. J. Med. Chern. 22, 433-437 (1987).

Greer, G., personal communication. Grinspoon, D., personal communication. Grinspoon, L., personal communication. Grof, S., personal communication. Gross, D., personal communication. Gross, P., personal communication. Grotjahn, D., personal communication. Hammond, M.L., Zambias, R.A., Chang, M.N., Jensen, N.P., McDonald, J.,

Thompson, K., Boulton, R.J ., Kopka, I.E., Hand, K.M., Opas, E.E., Luell, S., Bach, T., Davies, P., Macintyre, D.E., Bonney, R.J. and Humes, J.L., J. Med. Chern. 33,908-918 (1990).

Hansen, K., personal communication. Hardman, H.F., Haavik, C.O. and Seevers, M.H., Toxicol. Appl. Pharmacol. 25,

299-309 (1973). Harley-Mason, J., J. Chern. Soc. 200-203 (1953). Harlow, D., personal communication. Harris, R., personal communication. Henderson, G., personal communication. Herbert, P., personal communication. Hey, P., Quart. J. Pharmacy Pharmacol. 20, 129-134 (1947). Hipkiss, D., personal communication. Ho, B.T., Tansey, L.W., Balster, R.L., An, R., Mcisaac, W.M. and Harris, R.T.,

J. Med. Chern. 13, 134-135 (1970). Hoffman, A., personal communication. Hofmann, A., personal communication. Hollister, L.E. and Friedhoff, A.J., Nature 210, 1377-1378 (1966). Hope, T., personal communication. Horowitz, M., personal communication. Ishii, H., Ueda, E., Nakajima, K., Ishida, T., Ishikawa, K.l., Harada, K.l.,

Ninomiya, 1., Naito, T. and Kiguchi, T., Chern. Pharm. Bull. 26, 864 (1978). Jacob III, P., personal communication. Jacob III, P., Anderson III, G., Meshul, C.K., Shulgin, A.T. and Castagnoli Jr.,

N. J. Med. Chern. 20, 1235-1239 (1977). Jacob III, P., Kline, T. and Castagnoli Jr., N., J. Med. Chern. 22,662-671

(1979). Jacob III, P. and Shulgin, A.T., Syn. Commun. 11, 957 (1981). Jacob III, P. and Shulgin, A.T., Syn. Commun. 11, 969 (1981). Jacob III, P. and Shulgin, A.T., J. Med. Chern. 24, 1348 (1981). Jacob III, P. and Shulgin, A.T., J. Med. Chern. 26,746-752 (1983).

973


Jacob III, P. and Shulgin, A.T., J. Med. Chern. 27, 881 (1984). Jansen, M.P.J.M. Rec. Trav. Chim. 50, 291-312 (1931). Jones, H.B. and Jones, H. C., Sensual Drugs, Cambridge University Press,

Cambridge, 1977. Jones, R., personal communication. Joy, D., personal communication. Kahn, R.S., Wetzler, S., Asnis, G.M., Kling, M.A., Suckow, R.F. and van Praag,

H.M., Psychopharmacology 100, 339-344 (1990). Kaiser, C., Trost, B.M., Beeson, J. and Weinstock, J., J. Org. Chern. 30,3972-

3975 (1965). Kantor, R., personal communication. Kaplan, D., personal communication. Karoum, F., Potkin, S., Chuang, L.W., Murphy, D.L., Liebowitz, M.R. and

Wyatt, R.J., Bioi. Psychiat. 19, 165-178 (1984). Karoum, F., Potkin, S.G., Murphy, D.L. and Wyatt, R.J., Noncatecholic

Phenethylamines, Ed. Mosnaim and Wolf, Marcel Dekker, New York, 1980, p 178-191.

Kennedy, A., personal communication. Kline, T., personal communication. Klug, E. Deut. Apoth.-Ztg. (1971), Chern. Abst. 74:115965p. Kornfeld, H., personal communication. Kulkarni, A.S., Bioi. Psychiat. 6, 177 (1973). Lemaire, B., personal communication. Lemaire, D., personal communication. Lemaire, D., Jacob III, P. and Shulgin, A.T. J. Pharm. Pharmacol. 37, 575-577

(1985). Leminger, 0., Chern. Prum. 22, 553 (1972). Lenz, B., personal communication. Li, W.Y. and Lien, E.J., Bull. Oriental Healing Arts Inst. ofthe U.S.A. 8, 23-30

(1983). Lindeke, B., Paulsen-Sorman, U., Hallstrom, G., Khuthier, A-H., Cho, A.K. and

Krammerer, R.C. Drug Metab. Disp. 10,700-705 (1982). Love, W., personal communication. Lloyd, D., personal communication. Lombrozo, L., personal communication. Lopez, 1., personal communication. Luduena, F.P., C.R. Soc. Bioi. 121, 368 (1936). Mannich, C., Arch. Pharm. 242, 506 ( 1919). March, D.F. and Herring, D.A., J. Pharm. Exptl. Therap. 100,298-308 (1950). Mathis, C.A., personal communication. Mathis, C.A., Shulgin, A.T. and Sargent III, T., J. Labelled Compounds

Radiopharm. 23, 115-125 (1986). Mathis, C.A., Shulgin, A.T., Yano, Y. and Sargent III, T., Appl. Radiat. Isot.

Acknowledgements

37, 865-972 (1986). Matin, S.B., Callery, P.S., Zweig, J.S., O'Brien, A., Rapoport, R. and Castagnoli

Jr., N., J. Med. Chern. 17, 877-882 (1974). Matsuhiro, B. and Furst, A., J. Med. Chern. 13, 973 (1970). Mauthner, F., Ann. 499, 102 (1926). McKay, G., Cooper, J.K., Hawes, E.M., Roy, S.D. and Midha, K.K.,

Xenobiotica 13,257-264 (1983). McClure, M., personal communication. McKenna, D.J., personal communication. McKenna, D.J., Mathis, C.A., Shulgin, A.T., Sargent III, T. and Saavedra, J.M.,

Eur. J. Pharmacology 137, 289-290 (1987). McKenna, T., personal communication. McKinney, H., personal communication. Merchant, J.R. and Mountwala, A.J., Current Sci. (India) 26,211 (1957). Merchant, J.R. and Mountwala, A.J., J. Org. Chern. 23, 1774 (1958). Metzner, R., personal communication. Michaux, R., Experimental Brain Research 3, 178-183 (1967). Midha, K.K., Cooper, J.K., Bailey, K. and Hubbard, J.W., Xenobiotica 11, 137-

146 (1981). Millay, J., Personal communication. Mitchell, R., The Beaver, Spring, 1968 p 24-26. Mohandas, J., Slaytor, M. and Watson, T.R., Austral. J. Chern. 22, 1803-1804

(1969). Moore, J., personal communication. Moore, M.M., personal communication. Morin, R.D., Benington, F., Mitchell, S.R., Beaton, J.M., Bradley, R.J. and

Smythies, J.R., Experientia 31,93-94 (1975). Mueller, E.A., Sunderland, T. and Murphy, D.L., J. Clin. Endocrinol. Metab. 61,

1179-1184 (1985). Muller, A., Meszaros, M., Kormendy, K. and Kucsman, A., J. Org. Chem.17,

787-799 ( 1952). Naranjo, C., personal communication. Naranjo, C., The Healing Journey, Pantheon Books, Random Press, New York,

1973. Naranjo, C., Shulgin, A.T. and Sargent III, T., Med. Pharmacal. Exp. 17, 359-

364 (1967). Naylor, D.A., personal communication. Nichols, D.E., personal communication. Nichols, D.E., Barfknecht, C.F., Long, J.P., Standridge, R.T., Howell, H.G.,

Partyka, R.A. and Dyer, D.C., J. Med. Chern. 17, 161-166 (1974). Nichols, D.E., Barfknecht, C.F., Rusterholz, D.B., Benington, F. and Morin,

R.D., J. Med. Chern. 16,480-483 (1973). Nichols, D.E., Brewster, W.K., Johnson, M.P., Oberlender, R. and Riggs, R.M.,

975


J. Med. Chern. 33,703-710 (1990). Nichols, D.E. and Dyer, D.C., J. Med. Chern. 20, 299-301 (1977). Nichols, D.E., Hoffman, A.J., Oberlender, R.A., Jacob III, P. and Shulgin, A.T.,

J. Med. Chern. 29,2009-2015 (1986). Nichols, D.E., Hoffman, A.J., Oberlender, R.A. and Riggs, R.M., J. Med. Chern.

29, 302-304 (1986). Nichols, D.E. and Kostuba, L.J. J. Med. Chern. 22, 1264-1267 (1979). Nichols, D.E., Lloyd, D.H., Hoffman, A.J., Nichols, M.B. and Yim, K.W., J.

Med. Chern. 25,530-535 (1982). Nichols, D.E., Oberlander, R., Burris, K., Hoffman, A.J. and Johnson, M.P.

Pharmacol. Biochem. Behav. 34,571-576 (1989). Nichols, D.E. and Shulgin, A.T., J. Pharm. Sci. 65, 1554 (1976). Nichols, D.E., Shulgin, A.T. and Dyer, D.C., Life Sciences 21, 569-576 (1977). Nichols, D.E., Weintraub, J.R., Pfister, W.R. and Yim, G.K.W., NIDA Research

Monograph #22 QuaSAR of Analgesics, Narcotic Antagonists and Hallucinogens, U.S.G.P.O., 1978, p 70-83.

Nichols, D.E., Woodard, R., Hathaway, B.A., Lowy, M.T. and Yim, G.K.W., J. Med. Chern. 22, 458-460 (1979).

Noteboom, L. Proc. R. Acad. Amsterdam 37, 562 (1934). Oberlender, R.A., personal communication. Oberlender, R.A., Kothari, P.J., Nichols, D.E. and Zabik, J.E., J. Med. Chern.

27,788-792 (1984). Olender, B., personal communication. Olender, 1., personal communication. Orfali, S., personal communication. Pace, D., personal communication. Palmer, C., personal communication. Patra, A. and Mitra, A.K., J. Natl. Prod. 44, 668-669 (1981). Peretz, D.I., Smythies, J.R. and Gibson, W.C., J. Men. Sci. 101, 317-329 (1955). Peroutka, S.J., personal communication. Perry, A., personal communication. Perry, B., personal communication. Perry, J., personal communication. Perry, W., personal communication. Peterson, M., personal communication. Pitas, A., personal communication. Quincy, C., Personal communication. Repke, D., personal communication. Rheingold, H., personal communication. Ricaurte, G.A., personal communication. Riedlinger, J., personal communication. Riedlinger, T.J., personal communication. Ross, D., personal communication.

Acknowledgements

Saiki, Y., Sano, S. and Fukushima, S. Yaku. Zasshi 90, 103-106 (1970). Sager, R.K., personal communication. Santos, W., personal communication. Sapienza, F., personal communication. Sargent III, T., personal communication. Sargent III, T., Braun, U., Braun, G., Kusubov, N. and Bristol, K.S., Nucl. Med.

Bioi. 16, 91-99 (1989). Sargent III, T., Kalbhen, D.A., Shulgin, A.T., Braun, G., Stauffer, H. and

Kusubov, N., Neuropharmacology 14, 165-174 (1975). Sargent III, T., Shulgin, A.T. and Mathis, C.A., J. Labelled Compounds

Radiopharm. 19, 1307-1308 (1982). Sargent III, T., Shulgin, A.T. and Mathis, C.A., J. Med. Chern. 27, 1071-1077

(1984). Sargent, V ., Personal communication. Sayigh, A.A.R., Ulrich, H. and Green, M., J. Chern. Soc. 3482 (1964). Schoenfeld, E., personal communication. Schoonover, S., personal communication. Schwartz, J., Personal communication. Schweitzer, J.W. and Friedhoff, A.J., Am. J. Psychiatry 124, 1249-1253 (1968). Schweitzer, J.W., Friedhoff, A.J., Angrist, B.M. and Gershon, S., Nature 229,

133-134 (1971). Sepulveda, S., Valenzuela, R. and Cassels, B.K., J. Med. Chern. 15,413-415

(1972). Seymour, R., personal communication. Shulgin, A.T., unpublished findings. Shulgin, A.T., Nature 201, 1120-1121 (1964). Shulgin, A.T., Experientia 20, 336 (1964). Shulgin, A.T., Can. J. Chern. 43, 3437-3440 (1965). Shulgin, A.T., J. Med. Chern. 9, 445-446 (1966). Shulgin, A.T., Can. J. Chern. 46,75-77 (1968). Shulgin, A.T., British Patent 1,147,739 (1969). Shulgin, A.T., U.S. Patent 3,547,999 (1970). Shulgin, A.T., J. Psychoactive Drugs 18, 291-304 (1986). Shulgin, A.T. and Carter, M.F., Psychopharm. Commun. 1, 93-98 (1975). Shulgin, A.T. and Dyer, D.C., J. Med. Chern. 18, 1201-1204 (1975). Shulgin, A.T. and Jacob III, P., J. Anal. Tox. 6, 71 (1982). Shulgin, A.T. and Jacob III, P., Clinical Toxicology 19, 109 (1982). Shulgin, A.T. and Sargent III, T., Nature 215, 1494-1495 (1967). Shulgin, A.T., Bunnell, S. and Sargent III, T., Nature 189, 1011-1012 (1961). Shulgin, A.T., Sargent III, T. and Naranjo, C., Nature 212, 1606-1607 (1966). Shulgin, A.T., Sargent III, T. and Naranjo, C., Ethnopharmacologic Search for

Psychoactive Drugs. Public Health Publication #1645, D. Efron, Ed. 1967 p 202-214.

977


Shulgin, A.T., Sargent III, T. and Naranjo, C., Nature 221, 537-541 (1969). Shulgin, A.T., Sargent III, T. and Naranjo, C., Pharmacology 5, 103-107 (1971). Shulgin, A.T., Sargent III, T. and Naranjo, C., Pharmacology 10, 12-18 (1973). Shulgin, L.A., unpublished findings. Shulgin, T.A., personal communication. Siegel, R.K., personal communication. Slotta, K.H. and Muller, J., Z. physiol. Chern. 238, 14 (1936). Smythies, J.R., Personal communication. Snyder, J., personal communication. Spath, E. and Bruck, J., Chern. Ber. 70,2446 (1937). Spath, E. and Bruck, J., Chern. Ber. 71, 1275 (1938). Spencer, J., personal communication. Stafford, P., personal communication. Standridge, R.T., Howell, H.G., Gylys, J.A., Partyka, R.A. and Shulgin, A.T., J.

Med. Chern. 19, 1400-1404 (1976). Stanley, A.O., Personal communication. Stevens, J., personal communication. Stolaroff, J., personal communication. Stolaroff, M., personal communication. Strassman, R., personal communication. Tarcher, J ., personal communication. Tolbert, R., personal communication. Tozman, S., Schweitzer, J.W. and Friedhoff, A.J., Life Sciences 11, 1069-1078

(1972). Trampota, M., personal communication. Trudeau, G.B., Doonsbury, Universal Press Syndicate, August 12-24, 1985. Turek, I.S., Soskin, R.A. and Kurland, A.A., J. Psychedelic Drugs 6, 7-14

(1974). van der Schoot, J.B., Ariens, E.J., van Rossum, J.M. and Hurkmans, J.A.Th.M.,

Arzn. Forsch. 12, 902-907 (1962). Wang, Z.W., Ma, W.W. and McLaughlin, J.L., J. Nat. Prod. 51, 382 (1988). Weintraub, H.J.R., Nichols, D.E., Makriyannis, A. and Fesik, S.W., J. Med.

Chern. 23, 339-341 (1980). Weiss, J., Personal communication. Weiss, L., personal communication. Weinstock, J. J. Org. Chern. 26, 3511 (1961). Williams, P., personal communication. Winek, C.L., Collom, W.O. and Bricker, J.D., Clinical Toxicology 18,267-271

(1981). Wolfson, A., personal communication. Wolfson, P., personal communication. Zeff, L., personal communication. Zhingel, K., personal communication.

alexander & ann shulgin - pihkal - a chemical love story - appendices

Documents

aleph state

chemical love story

long index

t mmda